 
 
 
Reduced -Intensity  Fludarabine, Melphalan, and Total Body Irradiation 
Conditioning for Transplantation of HLA- Haploidentical Related 
Hematopoietic Cells (Haplo- HCT) For Patients With Hematologic 
Malignancies  
Protocol  Number:  MCC [ADDRESS_637802] Identified Number: NCI-2019- [ZIP_CODE]  
 
 
Principal  Investigator:  [INVESTIGATOR_43220], MD  
  
IND number : 144792  Exempt  
Biostatistician:  Jongphil Kim, PhD  
 
 
Funded by:  [CONTACT_496225]:  v 10    
  
 
 
 
 

  
  ii Table of Contents  
1 PROTOCOL SUMMARY  ............................................................................................................................... 1 
1.1 Synopsis  ................................................................................................................................................ 1 
Transplant Related Endpoints  ........................................................................................................................... 2 
1.2 Schema  ................................................................................................................................................. 4 
1.3 Schedule of Activities (SoA)  ............................................................................................................... [ADDRESS_637803] with ptcy  ........................................................................................................... 8 
2.4 Mycophenolate Mofetil Pharmacokinetics  ........................................................................................ 9 
2.5 Cyclopophosphamide Metabolism  .................................................................................................... 9 
2.6 Summary of Rationale  ........................................................................................................................ 9 
2.7 Risk/Benefit Assessment  .................................................................................................................. 10 
2.7.1  Known Potential Risks  ................................................................................................... 10 
2.7.2  Preparative Regimen  ..................................................................................................... 10 
2.7.3  Haploidentical Donor Stem Cell Infusion  .................................................................... 12 
2.7.4  GVHD Prophylaxis  ......................................................................................................... 12 
2.7.5  G-CSF  13 
2.7.6  Known Potential Benefits  .............................................................................................. 14 
2.7.7  Assessment of Potential Risks and Benefits  .............................................................. 14 
3 OBJECTIVES AND ENDPOINTS  .............................................................................................................. 14 
4 STUDY DESIGN  ........................................................................................................................................... 17 
4.1 Overall Design  .................................................................................................................................... 17 
4.2 Scientific Rationale for Study Design .............................................................................................. 17 
4.3 Justification for Dose  ......................................................................................................................... 17 
4.4 End of Study Definition  ..................................................................................................................... 17 
5 STUDY POPULATION  ................................................................................................................................ 18 
5.1 Inclusion Criteria  ................................................................................................................................ 18 
5.1.2  Eligible Diseases  ............................................................................................................ 18 
5.1.3  Organ Function Criteria  .................................................................................................  21 
5.2 Exclusion Criteria  ............................................................................................................................... 21 
5.3 Donor selection  .................................................................................................................................. 22 
5.4 Lifestyle Considerations  .................................................................................................................... 23 
5.5 Screen Failures  .................................................................................................................................. 23 
5.6 STRATEGIES FOR RECRUITMENT AND RETENTION  ............................................................ 23 
5.7 Patient Registration in oncore .......................................................................................................... 24 
6 STUDY INTERVENTION  ............................................................................................................................ 24 
6.1 Study Intervention(s) Administration  ............................................................................................... 24 
6.1.1  Study Intervention Description  ..................................................................................... 24 
Treatment Plan  .......................................................................................................................................................... 24 
6.1.2  Dosing and Administration  ............................................................................................ 24 
6.1.3  GVHD Prophylaxis and Growth Factor Support (begin Day 5)  ............................... 26 
6.1.4  Supportive care  .............................................................................................................. 27 
6.1.5  Follow -up ......................................................................................................................... 27 
6.2 Measures to Minimize Bias: Randomization and Blinding ........................................................... 27 
6.3 Study Intervention Compliance ........................................................................................................ 27 
  
  iii 6.4 Concomitant Therapy  ........................................................................................................................ 27 
6.4.1  Rescue Medicine  ............................................................................................................ 28 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  .................................................................................................................... 28 
7.1 Discontinuation of Study Intervention  ............................................................................................. 28 
7.2 Participant Discontinuation/Withdrawal from the Study  ............................................................... [ADDRESS_637804] to Follow -Up ............................................................................................................................... 29 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 30 
8.1 Efficacy Assessments ....................................................................................................................... 30 
8.2 Safety and Other Assessments  ....................................................................................................... 32 
8.3 BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES OR OTHER ENDPOINTS ........... 33 
8.3.1  Mycophenolate Pharmacokinetics  ............................................................................... 33 
8.3.2  Cyclophosphamide Pharmacogenomics  .................................................................... 34 
8.4 Adverse Events and Serious Adverse Events  ............................................................................... 34 
8.4.1  Definition of Adverse Events (AE)  ............................................................................... 34 
8.4.2  Definition of Serious Adverse Events (SAE)  .............................................................. [ADDRESS_637805]  ............................................................................................. 37 
8.4.9  Reporting of Pregnancy  ................................................................................................ 37 
8.5 Unanticipated Problems  .................................................................................................................... 37 
8.5.1  Definition of Unanticipated Problems (UP)  .................................................................  37 
8.5.2  Unanticipated Problem Reporting  ................................................................................ 38 
9 STATISTICAL CONSIDERATIONS  .......................................................................................................... 39 
9.1 Statistical Endpoints  .......................................................................................................................... 39 
Transplant Related Endpoints  ......................................................................................................................... 39 
9.2 Sample Size Determination  .............................................................................................................. 39 
9.3 Statistical Analyses ............................................................................................................................ 40 
9.3.1  General Approach  .......................................................................................................... 40 
9.3.2  Analysis of the Primary Efficacy Endpoint  .................................................................. 40 
9.3.3  Analysis of the Secondary Endpoints  ......................................................................... 40 
9.3.4  Mycophenolate Pharmacokinetic Analyses ................................................................ 41 
9.3.5  Cyclophosphamide Pharmacogenetic Analyses  ....................................................... 41 
9.3.6  Exploratory Analyses  ..................................................................................................... 41 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............................. 42 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ........................................................... 42 
10.1.1  Scientific Review Committee (SRC)  ............................................................................ 42 
10.1.2  The Protocol Monitoring Committee (PMC)  ............................................................... [ADDRESS_637806] (IRB)  .................................................................................. 43 
10.1.6  Informed Consent Process  ........................................................................................... 43 
10.1.7  Consent/assent and Other Informational Documents Provided to participants  .... [ADDRESS_637807] Policy  .............................................................................................. 49 
10.4  Additional Considerations  ................................................................................................................. 49 
10.5  Abbreviations  ...................................................................................................................................... 49 
10.6  Protocol Amendment History  ........................................................................................................... 51 
11 REFERENCES  ............................................................................................................................................. 52 
Appendix I Cytokine Release Syndrome Grading  ................................................................................................ 56 
Appendix II –  Karnofsky Performance Status  ....................................................................................................... 59 
Appendix III – TBI Guidelines  .................................................................................................................................. [ADDRESS_637808] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  1 1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  Reduced- Intensity  Fludarabine,  Melphalan, and Total Body 
Irradiation Conditioning for  Transplantation of HLA -Haploidentical 
Related Hematopoietic Cells (Haplo- HCT) For Patients With 
Hematologic Malignancies  
Study Des cription : This is a single arm, phase II trial of HLA -haploidentical related 
hematopoietic cells transplant (Haplo- HCT) using reduced intensity 
conditioning (fludarabine and melphalan and total body irradiation).  
Peripheral blood is the donor graft source.  This study is designed to 
estimate disease -free survival (DFS) at [ADDRESS_637809]-transplant.   
Objectives:  Primary Objective: The primary objective is to estimate probability of 
the 18 months  DFS after a  HLA-haploidentical related hematopoietic 
cells transplant (Haplo- HCT) using a  reduced intensity conditioning 
regimen with fludarabine/melphalan/total body irradiation (TBI) 
conditioning for patients with advanced age or comorbidities.   
 Secondary Objectives:  
• Incidence of day [ADDRESS_637810]-disease (GVHD)  
• Probability of 6 month and 18 months  treatment -related mortality 
(TRM)  
• Probability of 18 months  relapse incidence  
• Probability of 18 months overall survival (OS)  
 
 Transplant Related Objectives:  
• Incidence o f neutrophil recovery by [CONTACT_4475] +56  
• Incidence of platelet recovery by [CONTACT_4475] +56   
• Donor cell engraftment (chimerism) at day +30, +60, + 90, +180 and 
+ 365  
• Incidence of 1 year  and 18  months  chronic GVHD  
• Probability of 1 year  and 18 months  GVHD and relapse- free 
survival (GRFS)  
• Incidence of serious fungal and viral infections at day [ADDRESS_637811] 
 
Pharmacokinetic Objectives:  
• Evaluate pharmacokinetics of mycophenolate  mofetil (MMF) 
measured on day [ADDRESS_637812] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  2 • Evaluate single nucleotide polymorphisms (SNPs) in p450, 
aldehyde dehydrogenase, and glutathione S -transferase that 
influence Cyclophosphamide metabolism  
 
Endpoints:  Primary Endpoint: The primary endpoint is the probability of disease -
free survival (DFS) by [ADDRESS_637813] -transplant.  An event will be 
defined as death or a relapse 
 Secondary Endpoints:  
• Probability of Grade II -IV and Grade III -IV aGVHD at 180 days  
• Probability of TRM at 6 months and 18 months  
• Probability of rel apse at 18 months  
• Probability of 18 months year overall survival (OS)  
 
Transplant Related Endpoints  
• Probability of neutrophil recovery by [CONTACT_4475] + 56 
• Probability  of platelet recovery by [CONTACT_4475] +56  
• Proportion of donor cell engraftment (chimerism) at days + 30, 
+60, + 90, +180 and +365 
• Probability of 18 months  chronic GVHD  
• Probability of 18 months  GRFS  
• Probability of serious fungal and viral infections at day +100, [ADDRESS_637814] 
 
Pharmacokinetic Endpoints:  
• Concentrations of M MF metabolites measured on day 6  after 
transplant  
• Prevalence, by [CONTACT_124940], of SNPs in p450, aldehyde 
dehydrogenase, and glutathione S -transferase known to 
influence Cyclophosphamide metabolism   
Study Population:  
 Estimated Sample Size: 34 patients  
• Age > [ADDRESS_637815] -CI>3 
• Karnofsky performance status of ≥70% or Lansky play score ≥ 70%  
• Acute leukemia in complete remission  
or 
• Myelodysplastic syndrome, myeloproliferative neoplasm or chronic 
myelogenous leukemia with <5% blasts in bone marrow by 
[CONTACT_5293];  
or 
• High risk lymphoma in at least a partial remission (PR)  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  3 • The donor and recipi[INVESTIGATOR_496198] (using high resolution DNA based typi[INVESTIGATOR_007]) at the following 
genetic loci: HLA -A, HLA -B, HLA -C, and HLA -DRB1.   
Phase:  Phase II  
Description of 
Sites /Facilities  
Enrolling Participants:  H.  Lee Moffitt Cancer Center  - Single Site  
Description of Study 
Intervention : Conditioning:  
Day -6: Fludarabine IV 30mg/m2, Melphalan 70 mg/m2 
Day -5: Fludarabine IV 30mg/m2 
Day -4: Fludarabine IV 30mg/m2 
Day -3: Fludarabine IV 30mg/m2 
Day -2: Fludarabine IV 30mg/m2 
Day -1: Total Body Irradiation 2 Gy 
 
Graft:  
PBSCT infusion will be administered  on day 0 with a minimal dose of 
2x106 CD34+ cells and a maximum  dose of 5x106 CD34+ cells.  
 
GVHD Prophylaxis:  
Cyclophosphamide IV 50 mg/kg will be administered on Day +3 and 
+4. Mycophenolate mofetil (MMF) and sirolimus  will be initiated on 
day +5. Sirolimus will be dosed to a goal level of 8-14 ng/ml. In 
absence of GVHD, sirolimus may be tapered after day 90 and should 
be completed by [CONTACT_4475] 180. MMF will be started at a dose of 15 mg/kg 
every 8 hours with a maximum daily dose not to exceed 3 gm. MMF 
will be discontinued on day +35.   
 
Study Duration:  36 Months  
Participant Duration:  [ADDRESS_637816] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  4 1.2 SCHEMA  
 
 
1.3 SCHEDULE OF ACTIVITIES (SOA)  
 
For explanation of procedures, please see Section 8 (Study Assessments and Procedures).  
 
Pre-BMT work -up evaluations should be completed prior to initiation of conditioning 
chemotherapy within the screening windows defined in the table below. Evaluations done as a 
“standard of care” prior to consent on trial may be used for the trial screening if falling within the 
appropriate window from initiation of conditioning chemotherapy.  
Scheduled evaluations after screening and until engraftment may be performed +/ -3 days from the 
targeted date; assessments performed after engraftment and through Day 90 may be done +/ -10 
days of the targeted date.  After Day 90 assessments may be done +/ - 30 days of the targeted 
date.  In addition, targeted days may be altered as clinically appropriate.  
Activity  Pre-BMT  
Work -Up Day 1 To 
Engraftment1 Follow -Up Days 
42-90 Follow -Up ( >Day 9 0 
through Day 54 0) 
Consent  No Window     
Medical History  Within 30 days  Daily  weekly  X (day 180, 360, 54 0) 
Physical Exam  Within 30 days  Daily  weekly  X (day 180, 360, 54 0) 
RT consultation  No Window     
Karnofsky/Lansky  Within 30 days   day 90 X (day 180, 360, 54 0) 
GVHD Assessment   weekly start day 7  weekly, day 90 X (day 180, 360, 5 40) 
CBC/diff/plt  Within 30 days  Daily  weekly  X (day 180, 360 , 540) 
-8 
 -4 
 -5 
 -2 
 -3 
 0 
 -1 
 +40 
 +30 
 +20 
 +10 
 +5 
 +60 
 +50 
 +180  
  Flu 30 mg/m2/day          CY 50 mg/kg/day  
TBI 2Gy/day  
PBSCT infusion  
Siri
 
MMF  
G-CSF 
-7 
-6 
Mel 70 mg/m2 

RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  5 Activity  Pre-BMT  
Work -Up Day 1 To 
Engraftment1 Follow -Up Days 
42-90 Follow -Up ( >Day 9 0 
through Day 54 0) 
PT/INR  Within 60 days     
Viral Screen  Within 60 days     
PRA (Donor Specific 
Antibody)  Within 60 days     
Basic metabolic panel   Daily    
Comprehensive 
metabolic panel  Within 30 days  2x/wk  weekly  X (day 180, 360, 54 0) 
eGFR for adults with 
creat > 1.[ADDRESS_637817] ( females 
of childbearing potential)  Within 30 days     
BM Biopsy  Within 60 days  X (day 30 ) X (day 90) X (day 180, 360, 540)  
BM chimerism   BM (day 30)  BM (day 9 0) BM (day 180, 360, 
540) 
Blood chimerism    PB (day 30)  PB (day 90)  PB (day 180, 360, 
540) 
PETCT (lymphoma only)  Within 60 days    X 
Minimal Residual Disease  Within 60 days  BM (day 30) BM (day 9 0) BM (day 180, 360, 
540) 
T-Cell Immune 
Reconstitution Panel  Within 60 days  PB (day 30) PB (day 90) PB (day 180, 360, 
540) 
CMV PCR (blood)   Weekly  Weekly   
HHV6 PCR (blood)   Weekly  Weekly   
PFT/DLCO  Within [ADDRESS_637818]/Sinus  Within 60 days     
Disease Evaluation  Within 60 days  X (day  30) X (day 9 0) X (day 180, 360, 540)  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  6 Activity  Pre-BMT  
Work -Up Day 1 To 
Engraftment1 Follow -Up Days 
42-90 Follow -Up ( >Day 9 0 
through Day 54 0) 
Research Bone 
Marrow and Blood2 
Sample  No Window  X (day 30)  X (day 180)  
Blood samples  for 
MMF   X (day 7)3   
1 Engraftment defined as absolute neutrophil count (ANC) ≥ 5 X 108/L for 3 consecutive measurements  
2 Research blood samples will be used for cyclophosphamide genomics studies. Research blood samples will be 
collected in EDTA blood collection tubes  and research marrow samples will be collected in sodium heparin 
tubes . Excess blood and marrow samples  from existing samples  (including those collected for MCC [ZIP_CODE])  may 
be stored for future correlative studies  in lieu of collecting a new sample.  
3 Blood for MMF pharmacokinetic s tudies will be obtained on day 7  at the following time points: pre- dose, post -
dose, 1 hour, 2 hour, 4 hour, and 8 hours after dose in EDTA blood collection tubes.  Collections may occur +/ - 
10 minutes from the scheduled interval.  
NOTE: In certain clinical circumstances (e.g. relapsed or terminally ill patients , risk of undue harm 
to patients, etc. ) study tests may be omitted at the physician’s discretion. Additionally, t ests may be 
rescheduled as clinically indicated.  
 
2  STUDY RATIONALE AND BACKGROUND  
 
 
2.1 INTRODUCTION  
Allogeneic (allo) hematopoietic cell transplantation (HCT) is widely used as a curative therapy for  
a number of hematological malignancies.  While early conditioning regimens were too toxic for 
many patients, r educed intensity conditioning (RIC) opened opportunities for older patients and 
those with comorbid conditions to be eligible for potentially curable transplantation. [1-5]  
Historically, implementation of allo HCT required the availability of a human leukocyte antigen 
(HLA) matched donor to minimize complications including graft -versus -host disease (GVHD) and 
non-relapse mortality (NRM). An HLA matched sibling donor (MSD) is the preferred donor, but 
only 30% of patients have an MSD. [6] When no MSD exists, HLA matched unrelated donors 
(MUDs) may be identified through volunteer donor databases. However, the likelihood of finding a 
suitable MUD varies dramatically by [CONTACT_124940], from <20% for Black populations to ~75% for White 
Caucasian groups .[6] Overall, the likelihood of finding an HLA matched donor is 60%, and falls 
below  50% for many ethnic minority groups .[6, 7]   In addition, data from the National Marr ow Donor 
Program (NMDP) indicat es that the median time from donor search to adult MUD transplant is 
about 3- 4 months.  This time delay increases the risk of malignancy relapse in some patients with 
aggressive diseases. [1, 2]    
Given the absence of a matched donor for many patients, alternative donor strategies that use 
HLA mismatched donors have been developed to expand the donor pool. [8-11] Among the most 
commonly adopted strategies is the use of HLA haploidentical (HLA “half -matched”) related 
donors. Low cost and easy accessibility of haploidentical transplantation (haplo- HCT) make it an 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  7 attractive alternative graft source.  As HLA haplotypes follow Mendelian inheritance, the likelihoods 
of a sibling or offspring being HLA haploidentical to the patient are approximately 50% and 100%, 
respectively. Per prior reports, inclusion of HLA haploidentical donors in HCT donor search 
algorithms increases the likelihood of finding a suitable donor to >90%, even in  populations  for 
whom unrelated donors are less likely .[7, 12 -14] Thus, optimization of haplo HCT protocols allows 
for transplantation fo r nearly all patients otherwise eligible for  the procedure.  
2.[ADDRESS_637819] disease (GVHD) and transplant -related mortality (TRM) in 
about half of the patients. [15-17] A number of strategies have been attempted to reduce the toxicity 
of haplo HCT by [CONTACT_263303] T-cells, which facilitate GVHD. [14, 18 -27]  Ex vivo depletion of T- cells 
does reduce GVHD, but results in poor engraftment and unacceptably high rates of infection and 
TRM .[14, 18, 19]   
Investigators at the Johns Hopkins University developed a strategy that uses high dose post -
transplant cyclophosphamide (PTCy) to deplete T- cells in vivo .[28]  PTCy after transplant is 
preferentially toxic to the alloreactive T cells that cause GVHD while also sparing the regulatory T  
(Treg) cells that help induce immune tolerance. These effects result in a potent anti -GVHD effect 
that allows for safe transplantation from HLA mismatched donors. [29-31] The original Johns 
Hopkins PTCy platform uses a RIC regimen consisting of Fludarabine (Flu) 30 mg/m2/day IV daily 
from Days - 6 to -2, Cy 14.5 mg/kg IV on Day - 6 and - 5, and 200 cGy total body irradiation (TBI) in 
a single fraction on Day -1 (Flu150Cy29TBI200), bone marrow graft  (BMT), and PTCy 50 mg/kg 
given on days +3 and +4. [32-35] Multiple studies  have demonstrated acceptable toxicity with this 
platform including rates of TRM ~10- 15%, acute GVHD rates ~30%, severe acute GVHD rates of 
~10%, and chronic GVHD rates ~10% .[28, 36 -39]  Immune reconstitution is also favorable given 
preservation of memory T -cells when PTCy is used in T- cell replete haplo HCT. [23, 25]   
Prospective comparative trials comparing the Hopkins haplo BMT  with PTCy  platform  to other 
donor platforms are lacking. Results of two parallel Blood and Marrow Transplant Clinical trials 
Network (BMTCTN) multicenter phase 2 trials compared the outcomes of patients with RIC haplo 
BMT with PTCy (BMTCTN 0603, n=50) to  RIC umbilical cord blood transplantation (UCBT; 
BMT CTN 0604, n=50) .[40]  Recipi[INVESTIGATOR_496199]150Cy29TBI200 
and UCB T recipi[INVESTIGATOR_496200] 40mg/m2 Days -6 to -2, Cy 50 mg/kg Day -6 and  TBI 200 cGy 
Day -1 (Flu200/Cy50/TBI200).  GVHD prophylaxis for haplo BMTs  consisted of Cy 50 mg/kg IV on 
Days +3 and +4 followed by [CONTACT_496226] +5.  UCB recipi[INVESTIGATOR_496201] -3 for GVHD prophylaxis. The 1- year probabilities of OS and 
DFS were 54% and 46% afte r double UCB (dUCB) transplantation (n =50) and 62% and 48%, 
respectively, after haplo BMT (n= 50). The cumulative incidence of neutrophil recovery at day 56 
was 94% after dUCB and 96% after haplo BMT. The cumulative incidence of grade II -IV acute 
GVHD at Day 100 was 40% after dUCB and 32% after haplo BMT .  The 1- year cumulative 
incidences of TRM and relapse after dUCB transplantation were 24% and 31%, re spectively, and 
those for haplo BMT  were 7% and 45%, respectively. A phase III randomized, prospective trial 
comparing haplo BMT with PTCy to UCBT is ongoing ([STUDY_ID_REMOVED]). No studies have prospectively compared the Hopkins platform to HLA matched donor transplant, though multiple 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637820] demonstrated favorable safety outcomes and comparable OS with the 
haplo regimen. [37, 38, 41, 42]   
Given its safety, accessibility, and low cost , the haplo HCT with PTCy approach has become widely 
used in many transplant centers  when a matched donor is not available. [24, 26, 43 -50]     
2.[ADDRESS_637821] WITH PTCY  
Though Flu150Cy29TBI200 haploidentical BMT with PTCy has safely expanded the donor pool  
with low rates of TRM and GVHD , application has been marred by [CONTACT_496227], exceeding 40 -50% in some studies. [28, 36, 
37, 51]  Thus, various modifications have been attempted to optimize haplo BMT  with PTCy in 
these disease groups.     
Efforts to reduce relapse by [CONTACT_496228] c onditioning regimens with haplo HCT with PTCy 
in younger patients with AML lowered the risk of post -transplant relapse to 20- 45% without a 
substantial increase in TRM in some reports. [45, 50]   However, since myeloablative conditioning 
is not an option for older patients and for those with higher comorbidities (HCT- CI >3) due to an 
unacceptably high risk of TRM,  strategies identifying novel RIC regimen s can reduce the risk of 
relapse and improve survival after haplo HCT with PTCy are needed for those >55 years old or 
with comorbidities.   
Recently Flu/Mel phalan (Mel)  and Flu/Busulfan (Bu) RIC regimens were compared in the matched 
adult donor allo HCT setting for AML/MDS, with the flu/mel reg imen yielding significantly improved  
relapse rates and DFS.[52] The group from MD Anderson Cancer Center (MDACC) has attempted 
similarly to implement a melphalan based regimen in the setting of haplo HCT with PTCy. They 
recently repor ted their experience with haplo HCT with PTCy following conditioning with Flu 40 
mg/m2 Day -6 to - 3, Mel 100 mg/m2 Day -8 and either Thiotepa 5 mg/kg Day -7 or TBI 200 cGy 
(FM100) in patients 55 years and older. [49, 50]  Despi[INVESTIGATOR_496202] 1 -year relapse rates of 11-
19% with the Flu/Mel regimen in these studies, prolonged courses  of intensive immune 
suppression (MMF through Day +90 and Tac through Day +180) were required in order to minimize 
the risk of excessive acute GVHD. [49, 50]  Notably, high doses  of Mel exposure per kilogram of 
body weight (>3.5mg/kg) has been previously shown to increase the risk of oral mucositis and 
subsequent acute GVHD rates  in allo  HCT recipi[INVESTIGATOR_840]. [53] Intensification of conditioning with the 
addition Mel, though at a lower dose than used at MDACC, may result in a more favorable balance 
of efficacy and toxicity.  
In addition to conditioning, graft source is a modifiable variable that may be optimized in the setting 
of high risk for disease relapse. The original Hopkins haplo HCT with PTCy platform used bone 
marrow (BM) as the graft source. In the setting of MUD HCT, prospective data has shown that 
transplantation from peripheral blood stem cell grafts (PBSCT) results in higher rates of chronic 
GVHD than bone marrow transplantation (BMT), without any benefit in disease control. [54] Noting 
the effectiveness of PTCy in preventing chronic GVHD, the Center for International Blood and Marrow Transplant Research (CIBMTR) pursued a large retrospective study to assess outcomes 
of haplo PBSCT with PTCy versus BMT with PTCy. [55]  Though rates of GVHD remained higher 
in the PBSCT group, NRM remained comparable in the two groups. Further, pat ients receiving 
PBSCT experienced lower relapse rates (RR) and improved diseas e free survival (DFS) . These 
results are bolstered by [CONTACT_496229] a smaller retrospective analysis. [56] Thus, substitution 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637822] 
with PTCy platform.  
2.4 MYCOPHENOLATE MOFETIL PHARMACOKINETICS  
The PTCy platform includes mycophenolate mofetil (MMF) through day +35 after transplant as 
well as either tacrolimus or sirolimus. [28, 31, 57]  Tacrolimus/sirolimus levels are monitored and 
dosing is adjusted to ensure consistent therapeutic exposure. In contrast, MMF in this regimen is 
dosed at 15 mg/kg three times daily, up to a maximum of [ADDRESS_637823] outcomes. 
A study of 85 patients receiving reduced intensity matched unrelated donor (MUD) transplants, 
higher levels of MMF metabolites in the blood correlated with a higher risk of cytomegalovirus 
(CMV) activation and lower T- cell chimerism. [58] Investigators from the University of Minnesota 
found in 87 reduced intensity HCTs including matched related and unrelated donors 
demonstrated that low unbound blood MMF levels were correlated with higher risks of acute 
GVHD and graft failure. [59] Recently, the same group showed that weight -based dosing of MMF 
impacts outcomes, with higher weight -based dosing resulting in lower rates of GVHD but higher 
rates of relapse. [60] In combination with PTCy, the impact of variable MMF exposure and 
pharmacokinetics have not been studied.  
2.5 CYCLOPOPHOSPHAMIDE METABOLISM  
PTCy for GVHD prevention is dosed at 50mg/kg given on day +3 and day +4 based on a 
reduction in GVHD compared to giving only a single dose on day +3. [28, 31]  However, 
pharmacokinetic data with this platform is lacking. In other HCT settings, Cyclophosphamide 
metabolism has proven highly variable with high relative exposure correlating with increased 
toxicity and NRM. [61] Cyclophosphamide is metabolized through the cytochrome p450 system 
and subsequently detoxified by [CONTACT_496230] S -transferases. 
Polymorphisms in these pathways have been shown to correlate with efficacy and specific drug 
related toxicities in various malignancies, including relapse in the autologous transplant 
setting. [62, 63]  Notably, the patterns of expression of these polymorphisms vary across ethnic 
groups, translating into different drug responses in these groups. [64, 65]  As haplo HCT helps 
address the challenges of finding a donor for black and hispanic patients, a better understanding of the pharmacokinetics of PTCy in these groups is warranted.  
2.[ADDRESS_637824] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  10 We hypothesize that intensificati on of Flu150/Cy29/TBI200 haplo BMT with PTCy to Flu150/Mel 
70mg/m2/TBI200 haplo PBSCT with PTCy can successfully reduce the risk of relapse and improve 
DFS without substantially increasing the risk of TRM. Additionally, we will substitute sirolimus 
instead of tacrolimus given recent phase II data from Moffitt that this drug may confer more 
favorable rates of chronic GVHD when combined with PTCy  and peripheral blood stem cell 
grafts .[66] 
If successful, this intervention would further enhance the utility of haplo HCT to expand the donor 
pool to all eligible patients.   
 
 
 
 
 
 
2.7 RISK/BENEFIT ASSESSMENT   
 
2.7.[ADDRESS_637825] disease, and relapse of primary disease and its complications. Specific complications are listed  below.  
 
2.7.2  PREPARATIVE REGIMEN  
 
Fludarabine  
Common  Less Common  Rare  
• severe suppression of 
blood counts  
• diarrhea  
• anorexia  
• mucositis  
• nausea/vomiting  
• stomatitis  
• osteoporosis  
• dysuria  • chills  
• fever  
• GI bleeding  
• peripheral 
edema  
 • neurotoxicity  
- agitation and confusion  
- blurred vision  
- peripheral neuropathy  
- hearing loss  
- headache  
- cerebellar syndrome  
- blindness  
- coma  
- weakness  
• depression  
• insomnia  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  11 Fludarabine  
Common  Less Common  Rare  
• hemorrhagic cystitis (except in FA)  
• abnormal renal function test  
• autoimmune hemolytic anemia  
• deep venous thrombosis  
• aneurysms  
• pruritic skin rash  
• abnormal liver function/liver failure  
• constipation  
• transient ischemic attack  
• dysphagia  
• myalgia  
• arthralgia  
• renal failure  
 
Cyclophosphamide  
Common  Less Common  Rare  
• nausea/vomiting  
• mucositis  
• sterility  
• severe suppression of  
• blood counts  
• diarrhea  
• fluid weight gain/edema  
• alopecia  • hemorrhagic cystitis  
 • cardiomyopathy  
• skin rash  
• SIADH (Syndrome of Inappropriate 
Anti-diuretic Hormone)  
 
 
Melphalan  
Common  Less Common  Rare  
• nausea (at higher doses)  
• vomiting (at higher doses)  
• low white blood cell count with increased risk of 
infection  
• low platelet count with 
increased risk of bleeding  
• anemia (low red blood cell 
count) with symptoms like 
tiredness, paleness, or trouble catching breath  • short -term or long -term 
infertility (inability to have children)  
• weakness  
 • severe allergic reaction  
• loss of appetite  
• scarring (fibrosis) or inflammation of lungs  
• hair loss, including face and body hair  
• rash  
• itching  
• second type of cancer (may happen years after treatment)  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  12 Melphalan  
Common  Less Common  Rare  
• diarrhea  • death from lung damage or 
other causes  
 
Total Body Irradiation  
Common  Less Common  Rare  
• nausea and vomiting  
• diarrhea  
• cataracts  
• sterility (inability to have 
children)  
• endocrinopathies (hormone imbalance due 
to damage to the 
endocrine gland)  
• stunted growth in children  
• intestinal cramps  
• mucositis (mouth sores)  • parotitis (swelling and 
inflammation of the parotid 
gland)  
• interstitial pneumonitis (explained below in the damage to vital organs section)  
• generalized mild reddening of the skin  
• veno- occlusive disease (VOD -  
explained below in the damage to vital organs section)  • dysphagia (difficulty 
swallowing)  
• deformities of the 
backbone (vertebrae)  
• nephropathy (numbness 
or tingling in hands 
and/or feet)  
• risk of 2nd malignancy 
years later (when given along with 
chemotherapy)  
2.7.3  HAPLOIDENTICAL DONOR STEM CELL INFUSION  
With the cell infusion  
• Nausea and vomiting  
• Possible allergic reaction (including itching, hives, flushing [red face], shortness of 
breath, wheezing, chest tightness, skin rash, fever, chills, stiff muscles, or trouble 
breathing)  
General transplant related risks  
• Slow recovery of blood counts   
• graft failure  
• Cytokine release syndrome (CRS , see appendix  I for grading  and management ) 
• Graft -Versus -Host Disease (GVHD)   
• Other complications including:  
o damage to the vital organs  
o serious infections   
o relapse of disease or a new blood cancer   
o risk to the unborn 
2.7.[ADDRESS_637826] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  13 Sirolimus   
Common  Less Common  Rare, but may be serious  
 Pain or body aches  
 Fever  
 High blood pressure  
 kidney problems  
 Swelling of the hands, feet, 
ankles, or lower legs  
 Low red blood cell count 
(anemia)  
 Low platelets  
 Unusual bleeding/bruising  
 Headaches  
 Ulcers of the lips/mouth  
 Shortness of breath  
   Blood clots  
 High cholesterol  
 Reduced number of 
platelets, red, and white 
blood cells  
 Hoarse voice  
   Severe liver damage  
 Increased risk of 
lymphoma or other cancers  
 
 
Mycophenolate mofetil (MMF)  
Common  Less Common  Rare, but may be serious  
• miscarriage  
• birth defects  
• diarrhea  
• damage to unborn baby  
• limited effectiveness of birth 
control  
• stomach pain  
• upset stomach  
• vomiting  
• headache  
• tremors  
• low white blood cell count with increased risk of 
infection  
• increased blood cholesterols  
• swelling of the hands, feet, 
ankles or lower legs  • anemia  
• rash 
• difficulty falling asleep 
or staying asleep  
• dizziness  
• uncontrollable hand 
shakes  • difficulty breathing  
• unusual bruising  
• fast heartbeat  
• excessive tiredness  
• weakness  
• blood in stool  
• bloody vomit  
• change in vision  
• secondary cancers, such as lymphoproliferative disease or 
lymphoma  
• Progressive Multifocal 
Leukoencephalopathy  
2.7.5  G-CSF 
 
Common  Less Common  Rare, but may be serious  
none  • local irritation at injection site  
• ache or pain inside the bones  
• increased levels of liver enzymes  
• uric acid in the blood  
• low number of platelets in the blood  • allergic reaction, low fever  
• enlargement of the spleen and even 
splenic rupture  
• worsening of pre- existing skin rashes,  
• hair loss  
• inflammation of a blood vessel in the skin  
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637827] to expand the donor pool to all eligible patients. In 
particular, this would significantly improve outcomes in patients lacking an HLA matched donor and are, thus, at high risk of relapse using existing haplo transplant protocols.    
Immediate Benefits:  
• Decreased toxicity (GVHD, TRM) in the immediate post -transplant period as compared to 
many standard melphalan based conditioning regimens  
Long- range Potential Benefits:  
• Improved disease control  and survival  as compared to currently standard conditioning 
regimens used prior to haplo HCT with PTCy  
 
2.7.[ADDRESS_637828] can be generally categorized as disease free survival (i.e., 
cure), survival with disease relapse, and death due to transplant. Generally, increasing the 
intensity of pre- transplant conditioning results in lower relapse rates, but at the cost of higher 
rates of  transplant related mortality (TRM). Conversely, reduced intensity regimens decrease 
TRM but at cost of higher rates of  relapse. Thus, a large proportion of transplant patients 
succumb to either the transplant or disease relapse. The goal of this study is to use a novel 
conditioning regimen to optimize the balance of toxicity and efficacy in patients  undergoing 
haploidentical donor HCT with PTCy based GVHD prophylaxis.     
 
  
3 OBJECTIVES AND ENDPOINTS  
 
 
OBJECTIVES  ENDPOINTS  JUSTIFICATION 
FOR ENDPOINT S 
Primary    
The primary objective is to 
estimate probability of the 
18 month disease free 
survival (DFS) after a HLA -
haploident ical related 
hematopoietic cell  
transplant (Haplo -HCT) The primary endpoint is the probability of 
disease- free survival (DFS) by [ADDRESS_637829] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  15 OBJECTIVES  ENDPOINTS  JUSTIFICATION 
FOR ENDPOINT S 
using a reduced intensity 
fludarabine/melphalan/total 
body irradiation (TBI) 
conditioning in older 
patients in patients with a 
myeloid hematologic 
malignancy.  disease and overall 
survival.  
 
Secondary    
• Incidence of day [ADDRESS_637830]-disease (GVHD)  
• Probability of 6 month and 18 month TRM  
• Probability of 18 month 
relapse incidence  
• Probability of 18 month 
OS 
 • Probability of Grade II -IV and Grade 
III-IV aGVHD at 100 days  
• Probability of treatment -related 
mortality (TRM) at 6 months and  18 
months  
• Probability of relapse at 18 months   
• Probability of OS at [ADDRESS_637831] 
following transplant. 
These outcomes will 
further elucidate 
causes of treatment 
failure contributing to 
the primary outcome 
(DFS).  
Tertiary/ Exploratory    
• Incidence of neutrophil 
recovery by [CONTACT_4475] +30  
• Incidence of platelet 
recovery by [CONTACT_4475] +60  
• Donor cell engraftment (chimerism) at day + 30, 
+60, + 90, +180 and + 
365 
• Incidence o f 18 month 
chronic GVHD  
• Probability of 18 month year GVHD and relapse-
free survival (GRFS)  
• Incidence of 100 day, 1 
year, and 18 month 
serious fungal and viral 
infection  • Probability of neutrophil recovery by 
[CONTACT_4475] +30  
• Probability of platelet recovery by 
[CONTACT_4475] +60  
• Proportion of donor cell engraftment 
(chimerism) at days + 30, +60, + 90, 
+180 and +365  
• Probability of 18 month chronic 
GVHD 
• Probability of 18 month GVHD and 
relapse- free survival (GFRS)  
• Probability of [ADDRESS_637832] 
following transplant. 
These outcomes will 
further elucidate 
causes of treatment 
failure contributing to the primary outcome 
(DFS).
 
Pharmacologic    
• Evaluate 
pharmacokinetics of 
mycophenolate 
mofetil  (MMF) 
measured on day 6  
after transplant  
• Evaluate single 
nucleotide 
polymorphisms (SNPs) in p450, 
aldehyde • Concentrations of M MF 
metabolites measured on day 6 
after transplant  
• Prevalence, by [CONTACT_124940], of SNPs in p450, aldehyde 
dehydrogenase, and glutathione 
S-transferase known to 
influence Cyclophosphamide metabolism  
 • Metabolism of 
relevant drugs 
may impact 
clinical 
outcomes.  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637833] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  17 4 STUDY DESIGN  
 
4.1 OVERALL  DESIGN  
This is a single institution phase II study of a reduced intensity conditioning (RIC) followed by a 
haploidentical hematopoietic cell transplant (haplo- HCT) in persons with diagnosis of  
myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) .   
Conditioning will consist  of a reduced intensity  fludarabine, melphalan and total body irradiation 
(TBI) preparative regimen for patients ≥[ADDRESS_637834] Comorbidity Index (CI) > 3. 
The graft source will be peripheral blood stem cells.  
 
4.[ADDRESS_637835] with PTCy based GVHD prophylaxis. [67-69] These regimens are standard 
of care in allogeneic transplant at higher doses, so a phase I portion is not required in this study that will use a lower dose to decrease toxicity. This trial will determine the estimated efficacy of 
this regimen based on DFS  at 18 months . This will allow a basis for future, larger comparative 
studies.  
 
4.3 JUSTIFICATION FOR DOSE  
Recently Flu/Mel and Flu/Bu RIC regimens were compared in the matched adult donor allo HCT 
setting for AML/MDS, with the F lu/Mel regimen yielding significantly improved relapse rates and 
DFS. [52] The group from MD Anderson Cancer Center (MDACC) has attempted similarly to 
implement a melphalan based regimen in the setting of haplo HCT with PTCy. They recently reported their experience with haplo HCT with PTCy following conditioning with Flu 40 mg/m
2 Day 
-6 to - 3, Mel 100 mg/m2 Day -8 and either Thiotepa 5 mg/kg Day - 7 or TBI 200 cGy (FM100) in 
patients 55 years and older. [49, 50]  Despi[INVESTIGATOR_496202] 1- year relapse rates of 11 -19% with the 
Flu/Mel regimen in these studies, prolonged courses of intensive immune suppression (MMF 
through Day +90 and Tac through Day +180) were required in order to minimize the risk of 
excessive acute GVHD. [49, 50]  Notably, high dose of Mel exposure per kilogram of body weight 
(>3.5mg/kg) has been previously shown to increase the risk of oral mucositis and subsequent acute GVHD rates in allo HCT recipi[INVESTIGATOR_840]. [53] Thus, a reduction in melphalan dosing may result in 
a more favorable balance of efficacy and toxicity.  
 
4.[ADDRESS_637836] scheduled procedure shown in the S chedule of Activities 
(SoA), Section 1.[ADDRESS_637837] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  18  
5 STUDY POPULATION 
 
5.1 INCLUSION CRITERIA  
5.1.1  Age, Performance Status, and Graft Criteria  
• Age ≥ [ADDRESS_637838] Co-Morbidity score (HCT -CI) > 3 
(http://www.qxmd.com/calculate- online/hematology/hct -ci) 
• Lack of a suitable 8/8 HLA -matched sibling donor  
• Adequate performance status is defined as Karnofsky score ≥ 70%  (> 16 years 
of age) or Lansky score ≥ 70 (pediatrics) (Appendix I I) 
• Patients and selected donor must be HLA typed at high resolution using DNA 
based typi[INVESTIGATOR_496203] -loci: HLA -A, -B, -C and DRB1. Donors must 
be HLA -haploidentical relatives including, but not limited to, children, siblings, or 
parents, defined as  having a shared HLA haplotype between donor and patient 
at HLA -A, -B, -C, and -DRB1.Refer to donor selection in section 5 .3.  
5.1.2 Eligible Diseases  
Acute Myeloid Leukemia (AML) :  Must be in remission by [CONTACT_5293] (<5% 
blasts). Note cytogenetic relapse or persistent disease without morphologic relapse is acceptable. Also a small percentage of blasts that is equivocal between marrow regeneration vs. early relapse are acceptable pr ovided there are no associated 
cytogenetic markers consistent with relapse. (Refer to exclusion criteria section 3.5 
for more detailed definition).   
• Second or greater complete remission (CR)  
• First CR (CR1) in patients ≥60 years old  
• CR1 in <60 years old that is NOT considered as favorable risk  (see 
exclusion criteria) .   
o Acute prolymphocytic leukemia (APL) in first molecular remission at the end of consolidation  
Acute lymphoblastic leukemia (ALL)/lymphoma: second or greater CR ; CR1 
unable to tolerate consolidation chemotherapy due to chemotherapy -related 
toxicities; CR1 high -risk ALL.    
High risk ALL is defined as having one of the following:  
• Evidence of high risk cytogenetics, e.g. t(9;22), t(1;19), t(4;11), other MLL  
rearrangements, IKZF1  
• Recipi[INVESTIGATOR_29039] 30 years and older at diagnosis  
• White blood cell counts of greater than 30,000/mcL (B -ALL) or greater than 
100,000/mcL (T- ALL) at diagnosis  
• CNS leukemia involvement during the course of disease 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  19 • Slow cytologic response (>10% lymphoblasts in bone marrow on Day 14 of 
induction therapy)  
• Evidence of persistent immonophenotypic or molecular MRD at the end of 
induction and consolidation therapy  
Biphenotypic/Undifferentiated/Prolymphocytic Leukemias in first or 
subsequent CR . 
Myelodysplastic syndrome:  any subtype including refractory anemia (RA) if 
severe pancytopenia or complex cytogenetics. Blasts must be less than 10%. If 
10% or more , then  requires chemotherapy for cytoreduction to ≤ 10% prior to 
transplantation.  
Chronic myelogenous leukemia in chronic or accelerated phase.  Chronic 
phase patients must failed at least two different TKIs, been intolerant to all available TKIs or have T315I  mutation.  Accelerated phase requires remission as defined in 
“AML” section above.  
Myeloproliferative neoplasms/myelofibrosis.  Blasts must be less than 5%. If 5% 
or more requires chemotherapy for cytoreduction to ≤5% prior to transplantation.  
Relapsed large -cell lymphoma, mantle- cell lymphoma and Hodgkin 
lymphoma that is chemotherapy sensitive and has failed or ineligible for an 
autologous transplant.  
Burkitt’s lymphoma  in CR2 or subsequent CR.  
Relapsed T -cell lymphoma that is chemotherapy sensitive in CR/PR that has 
failed or ineligible for an autologous transplant.  
Natural Killer cell malignancies.  
Relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma 
(CLL/SLL), marginal zone B -cell lymphoma, follicular lymphoma  with any of 
the following:   
• Progressed within 12 months of achieving a partial or complete remission.  
• Patients who had remissions lasting > [ADDRESS_637839] 
two prior therapi[INVESTIGATOR_014].  
• Patients with primary refractory disease.  
 
Note: Bulky disease and an estimated tumor doubling time of less than one 
month  require debulking therapy prior to transplant .  
Lymphoplasmacytic lymphoma  is eligible after initial therapy if chemotherapy 
sensitive.  
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637840] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  21 5.1.3 Organ Function Criteria  
Adequate organ function is defined as:  
Cardiac: Absence of decompensated congestive heart failure, or uncontrolled 
arrhythmia and left ventricular ejection fraction > 40%.  For children that are not 
able to cooperate with MUGA and echocardiography, such should be clearly stated 
in the physician’s note  
Pulmonary: DLCO, FEV 1, FVC > 40% predicted, and absence of O [ADDRESS_637841] can be obtained it should be clearly stated in 
the provider’s note.  
Liver: Transaminases < 5 x upper limit of normal (ULN) and total bilirubin ≤ 2.5 
mg/dL except for patients with Gilbert’s syndrome or hemolysis.  
Renal: Creatinine < 2.0 mg/dL (adults) and creatinine clearance > 40 mL/min 
(pediatrics) .  Adults with a creatinine > 1.[ADDRESS_637842] estimated creatinine clearance > 40 ml/min/1.73m2. 
5.1.[ADDRESS_637843] agree to use adequate birth control during study treatment.   
5.1.5  Voluntary written consent (adult or parent/guardian with presentation of the minor 
information sheet, if appropriate)  
 
 
5.[ADDRESS_637844] feeding. The agents used in this study include Pregnancy 
Category D: known to cause harm to a fetus.  Females of childbearing potential 
must have a negative pregnancy test prior to starting therapy.  
5.2.[ADDRESS_637845] at any time point or less than 6 months since prior autologous 
transplant (if applicable)  
5.2.[ADDRESS_637846] changes indicating progression.  
5.2.6 Active central nervous system malignancy  
5.2.7 Favorable risk AML defined as having one of the following:  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  22 • t(8,21) without cKIT mutation or evidence of immunophenotypic, cytogenetic 
or molecular minimal residual disease (MRD)  
• inv(16) or t(16;16) without cKIT  mutation or evidence of MRD  
• Normal karyotype with mutated NPM1  but FLT3- ITD wild type without 
evidence of MRD  
• Normal karyotype with double mutated CEBPA without evidence of MRD  
5.[ADDRESS_637847] operating procedures of the Moffitt Cancer Center Department of 
Blood and Marrow Transplantation. H owever information in this protocol (including match 
criteria, donor selection priority if more than 1 available donor, cell collection target) overrules 
those procedures . 
In addition, the following  criteria  must be met:  
5.3.[ADDRESS_637848] be HLA -haploidentical relatives of the patient (biological parents, siblings, half -
siblings, offspring, or other non -first degree relatives ), defined as having a shared 
HLA haplotype between donor and patient at HLA -A, -B, -C, and - DRB1  
5.3.[ADDRESS_637849] 
within 7 days of marrow collection 
Donor Prioritization Schema  
In the event that two or more eligible donors are identified, the following order of priority is 
suggested:  
• Medically fit to donate  
• Absence of recipi[INVESTIGATOR_496204] -specific anti -HLA antibodies (DSA). Positive DSA is defined 
as a positive crossmatch test of any titer (by [CONTACT_30937] -dependent cytotoxicity or flow 
cytometric testing) or the presence of DSA to the high expression loci HLA -A, - B, -C, or 
-DRB1 with mean fluorescence intensity >1000 by [CONTACT_496231].  
• Donor age 18- 40 is prioritized over donor age < 18, then >40- 60 years . If multiple 18- 40 
year old donors are available, the donor should be selected based on the following 
criteria .  
• Lack of major ABO incompatibility  
• For cytomegalovirus (CMV) seronegative recipi[INVESTIGATOR_840], a CMV seronegative donor . For 
CMV seropositive recipi[INVESTIGATOR_840], a CMV seropositive donor.  
• Lack of minor ABO incompatibility  
• Male donor or non- parous female are preferable.  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637850] -transplant care per Moffitt Cancer Center 
BMT/CI standard operating procedures.  
 
5.5 SCREEN FAILURES  
 
Screen failures are defined as participants who consent to participate in the clinical trial but are 
not subsequently assigned to the study intervention or entered in the study. A minimal set of screen 
failure information is required to ensure transparent reporting of screen failure participants , to meet 
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details, eligibility criteria, and any serious adverse event (SAE).  
 Screen failure i ndividuals  who do not meet the criteria for participation in this trial because of a 
correctable comorbidity (e.g., active infection, elevated blast percentage, etc.)  may be rescreened. 
Rescreened participants should be assigned the same participant number as for the initial 
screening.  
 
5.6 STRATEGIES FOR RECRUITMENT AND RETENTION 
 
All the patients evaluated at Moffitt Cancer Center BMTCI department will be considered for this 
trial if they are otherwise eligible. Women and minorities will be enrolled if they are considered for 
haploidentical related hematopoietic Cells (Haplo- HCT)   and meet eligibility criteria. All efforts will 
be made to conform to NIH Policy on Inclusion of Women and Minorities as Participants i n 
Research Involving Human Subjects. This trial is expected to enroll a high proportion of ethnic 
minorities as these patients are less likely to have matched donor options. Demographic 
information regarding ethnicity/race will be collected for future reporting.  This information may be 
collected at any time after consent through the end of the trial. Patients will be followed for 1.[ADDRESS_637851].  
 
To facilitate collection of demographic data, patients will be asked to answer the following 
survey:  
 
“In this trial we want to accurately collect the race and ethnicity of all our patients. Please check 
the race/ethnicity category that you belong to:  
1.White  
2.Black or African American  
3.Hispanic  
4.American Indian or Alaska native  
5.Asian, Hawaiian or pacific islander  
6.Other, not included, please explain: ” 
  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  24 5.7 PATIENT REGISTRATION IN ONCORE  
Registration will occur after the patient/guardian has signed the subject consent and eligibility is 
confirmed.  To be eligible for registration to this study, the patient must meet each criteria listed on 
the eligibility checklist based on the eligibility assessment documented in the patient’s medical 
record.  A copy of the eligibility checklist is under attachments within the study in OnCore.  
Patients will be registered in OnCore by [CONTACT_496232]’s Clinical Trial Coordinator(s).  
 
6 STUDY INTERVENTION  
 
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
 
6.1.1  STUDY INTERVENTION  DESCRIPTION  
TREATMENT PLAN 
In order to provide optimal patient care and to account for individual medical conditions, 
investigator discretion may be used in the prescribing of all s upportive care drug therapy (e.g ., 
acetaminophen, diphenhydramine, antimicrobials, etc.).  
The administration of the preparative regimen will follow institutional drug and supportive care guidelines. Timing of infusions below may be modified per institutional practice or as clinically 
indicated.   
Dose and/or schedule adjustments to the dosing or administration of the treatment plan may be 
made on an individual patient basis as needed for safety  (e.g., for drug -drug interactions or 
toxicity) . 
All drugs used in this study are commercially available by [CONTACT_50246].  
 
6.1.2 DOSING AND ADMINISTRATION  
 
Treatment 
Day Treatment  Protocol 
Section  
Day –6 Fludarabine 30 mg/m2 IV over 30- 60 minutes, then  
Melphalan 70 mg/ m2 IV over 45 minutes [IP_ADDRESS]  
Days -5 Fludarabine 30 mg/m2 IV over 30 -60 minutes, then  [IP_ADDRESS]  
Day -4 Fludarabine 30 mg/m2 IV over 30 -60 minutes  [IP_ADDRESS]  
Day -3 Fludarabine 30 mg/m2 IV over 30- 60 minutes  [IP_ADDRESS]  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  25 Day -2 Fludarabine 30 mg/m2 IV over 30 -60 minutes  [IP_ADDRESS]  
Day -1 TBI 200 cGy  [IP_ADDRESS]  
Appendix II I 
Day 0  Peripheral Blood Stem Cell Transplant  [IP_ADDRESS]  
Day 3  Cyclophosphamide 50 mg/kg IV  
Mesna IV  [IP_ADDRESS]  
Day 4  Cyclophosphamide 50 mg/kg IV  
Mesna IV  [IP_ADDRESS]  
Day 5  Begin sirolimus , mycophenolate mofetil, and G -CSF 6.1.3  
[IP_ADDRESS]  CONDITIONING REGIMEN  
Fludarabine  30 mg/m2/day will be administered over 30 -60 minutes intravenous infusion on Days 
–6 through – 2 for a total dose of 150 mg/m2.  Fludarabine will be dosed according to the recipi[INVESTIGATOR_841]’s 
actual body weight.  For patients who have an estimated or measured creatinine clearance < 70 
ml/min/1.73 m2, or either prior CNS disease, prior brain radiation, or prior intrathecal 
chemotherapy, the fludarabine dose should be reduced by 20%.  Fludarabine dosing is based on 
the last creatinine clearance prior to the start of conditioning.  The fludarabine dose should be the 
same on Days - 6 to - 2, even if the patient’s creatinine changes.   
Melphalan  70 mg/m2 over 45 minutes will be administered on Day –6. Melphalan dose will be 
calculated based on Actual Body Weight. High -dose melphalan will be administered following oral 
cryotherapy per standard institutional  practice. High-dose Melphalan is administered via a central 
venous catheter following reconstitution with the provided sterile diluent. High- dose melphalan 
should be administered diluted with sodium chloride and infused over 45  minutes. Vigorous 
maintenance hydration will be administered with high dose melphalan per institutional practice 
(day –6).  
TBI 200 cGy will be administered on Day -1.  Refer t o appendix II . 
 
[IP_ADDRESS]  HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL  COLLECTION AND INFUSION (DAY 0)  
On day 0, patients will receive a peripheral blood hematopoietic cell graft. Donor peripheral blood 
hematopoietic cells will be collected for a target yield of 5 x 106 CD34+ cells/kg, minimal accepted 
number is 2 x 106 CD34+ cells/kg recipi[INVESTIGATOR_43223]. The maximum infused cell dose will be 7  x 106 
CD34+ cells/kg. Sample of the infused graft will be sent for flow cytometry to determine the content 
of CD34+, CD3+ cells and for correlative studies.  
[IP_ADDRESS]  POST -TRANSPLANT CYCLOPHOSPHAMIDE (DAY 3 AND DAY 4)  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  26 Hydration will be given according to our institutional standards.  
Cyclophosphamide 50  mg/kg will be given as an IV infusion over 1  hour on Days +[ADDRESS_637852] -transplant 
(between 62  and 72 hours after start of stem cell  infusion) and on Day + [ADDRESS_637853] -transplant 
(approximately 24 hours after Day + 3 cyclophosphamide).   
Mesna 20 mg/kg will be given as an IV infusion over 15 minutes for four doses on Days +[ADDRESS_637854] -
transplant and for four doses on Day +[ADDRESS_637855] dose of cyclophosphamide, then 3, 6, and 9 hours following the start of 
cyclophosphamide infusion each day.  
Both c yclophosphamide and mesna dosing is calculated based on ideal body  weight  (IBW ) unless 
actual body weight ( ABW ) is < IBW (then ABW should be used).   
Ideal body weight is calculated using 50kg + [2.3kg x  (height in inches – 60)] for men; 45.5kg + 
[2.3kg x  (height in inches –  60)] for women.   
6.1.3  GVHD PROPHYLAXIS AND GROWTH FACTOR SUPPORT (BEGIN DAY 5) 
All patients will receive prophylaxis for GVHD with two drugs both beginning at Day 5 as follows:  
[IP_ADDRESS]  SIROLIMUS  
Sirolimus (SIR) will be administered as a 9 mg oral loading dose on day +5, followed by  4 mg oral 
daily as  maintenance to target blood level 5- 14 ng/ml. SIR levels will be monitored according to 
BMT program standard operating procedures (BMT- G-103).  Serum levels of sirolimus will be 
measured around Day +7 and then should be checked twice weekly thereafter and the dose 
adjusted accordingly to maintain a goal trough level of 8-14 ng/mL.  Frequency of sirolimus levels 
may be decreased once the goal target has been achieved. Sirolimus  should be continued for at 
least 90 days if tolerated. In absence of GVHD, sirolim us should be discontinued by [CONTACT_4475] 180.    
The goal sirolimus trough may be adjusted as clinically indicated (e.g., for GVHD, infection, graft 
failure, relapse). Tacrolimus (trough level of 5-15 ng/ml) may be substituted for sirolimus if the 
patient is intolerant of sirolimus.   
[IP_ADDRESS]  MYCOPHENOLATE MOFETIL (MMF)  
MMF will be initiated  at a dose of 15 mg/kg PO TID (based upon actual body weight) with the 
maximum total daily dose not to exceed 3 grams (1 g PO TID). Dosing may be adjusted for toxicity 
or as clinically indicated.  MMF prophylaxis will begin on Day +[ADDRESS_637856] dose on Day +35 as tolerated or may be continued if active GVHD is 
present.   
 
[IP_ADDRESS]  GROWTH FACTOR SUPPORT  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  27 G-CSF will be given beginning on Day +5 at a dose of 300 mcg if patient weight is ≤ 70 kg or 480 
mcg if the patient weight is >70 kg. (rounding to the nearest vial dose is allowed), until absolute 
neutrophil count (ANC) is ≥ 1,500/mm3 for three consecutive measurements on 3 different days.  
G-CSF may be restarted to maintain ANC > 1,000/mm3.  G-CSF may be given by [CONTACT_496233].  
 
 
6.1.4  SUPPORTIVE CARE  
Supportive care will be provided per Moffitt Cancer Center’s institutional guidelines for transplant 
patients including any supportive care research protocols.  
All patients will receive standard supportive transfusion care according to transfusion committee 
guidelines or as modified based on clinical parameters.  
Acute and chronic GVHD will be staged and treated using current Moffitt Cancer Center BMT- CI 
program GVHD protocols   
Antimicrobial prophylaxis directed towards bacteria, fungi and viruses will be per Moffitt Cancer 
Center’s current institutional guidelines for transplant patients.  
 
 
6.1.[ADDRESS_637857] hematopoietic stem cell 
transplantation protocol for long- term follow -up.  
 
6.2 MEASURES TO MINIMIZE BIAS: RANDOMIZATION AND BLINDING  
 
Not Applicable 
 
6.3 STUDY INTERVENTION  COMPLIANCE  
 
Patients will admitted for conditioning and treatment in the inpatient BMT unit at the Moffitt Cancer 
Center from the initiation of conditioning through neutrophil engraftment. Patients will subsequently 
follow- up as outpatient per institutional protocol and the clinical trial calendar. Compliance with 
sirolimus  (or tacrolimus) will be assessed via serum levels. Compliance with other medications will 
be confirmed at follow -up visits.  
 
6.[ADDRESS_637858] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  28  
6.4.1 RESCUE MEDICINE  
 
Not applicable 
 
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT  
DISCONTINUATION/ WITHDRAWAL  
 
7.1 DISCONTINUATION  OF STUDY INTERVENTION 
 
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_87077], funding 
agency, the IND/IDE sponsor and regulatory authorities. If the study is prematurely terminated or 
suspended, the PI [INVESTIGATOR_33894](s) for the termination 
or suspension.  
 Circumstances that may warrant termination or suspension include, but are not limited to:  
 
• Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
 
The PMC and/or IRB may vote to suspend or terminate approval of a research study not being 
conducted in accordance with the IRB, the Cancer Center and/or regulatory requirements or that 
has been associated with unexpected problems or serious harm to subjects.  The PMC/IRB will 
notify th e PI [INVESTIGATOR_496205].  It is the responsibility  of the PMC/IRB 
Chairperson to ensure prompt written notification of any suspensions or terminations of PMC/IRB 
approval to the relevant Federal Agencies, including OHRP, FDA as applicable.  
 
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE STUDY  
 
Participants are free to withdraw from participation in the study at any time upon request. An 
investigator may discontinue or withdraw a participant from the study for the following reasons:  
 
• Pregnancy  
• Significant study intervention non- compliance  
• If any clinical adverse event (AE), laboratory abnormality, or other medical condition or 
situation occurs such that continued participation in the study would not be in the best 
interest of the participant  
• Disease progression which requires discontinuation of the study intervention 
• If the participant meets an exclusion criterion (either newly developed or not previously recognized) that precludes further study participation 
The reason for participant discontinuation or withdrawal from the study will be recorded within 
the patient’s medical record and OnCore and/or the Clinical Trial Management System 
(CTMS). Subjects who sign the informed consent form but do not receive the s tudy 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  29 intervention may be replaced.  Subjects may be replaced if they signed the informed consent 
form and received the study intervention, and then were withdrawn or discontinued from the 
study.  
All efforts will be made to continue to follow -up of withdrawn or terminated participants or 
participants who discontinue therapy  but remain in the study for follow -up, especially for 
safety and efficacy study endpoints (if applicable). Every effort will be made to undertake 
protocol -specified safety follow -up procedures to capture AEs, serious adverse events 
(SAEs), and unanticipat ed problems (UPs).  
 
7.[ADDRESS_637859] be taken if a participant fails to return to the clinic for a required study 
visit: 
• The site will attempt to contact [CONTACT_62541] 2 
weeks  and counsel the participant on the importance of maintaining the assigned visit 
schedule and ascertain whether the participant wishes to and/or should continue in the 
study.  
• Before a participant is deemed lost to follow -up, the investigator or designee will make 
every effort to regain contact [CONTACT_6635] (where possible, by [CONTACT_7328] 3 telephone 
calls and, if necessary, by [CONTACT_5583] a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact [CONTACT_62542]’s medical record or study file.  
• A minimum of [ADDRESS_637860] to 
follow- up.] 
  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637861] -transplantation study visits occur on day 30, 90, 180, 1 year, 
and 18 months (with acceptable windows as outlined in the study calendar).  
 
All clinic assessments and laboratory studies needed to inform study endpoints captured at these 
time points are part of Moffitt standard practices  (with exception of underlined research samples).  
 
1. Day 30 study visit  
- Capture ANC/PLT engraftment data, day 30 disease response assessment and donor 
chimerism, and any occurrence of acute GVHD  
- Monitor AE/SAE throughout observation period  
- Collect day [ADDRESS_637862] day 30 research blood sample and bone marrow sample 
 
3. Day 90 study visit  
- Capture acute GVHD data, day 90 disease response assessment and  donor chimerism, 
and death events.  
- Capture initiation of sirolimus (or tacrolimus ) taper.  
- Monitor AE/SAE throughout observation period  
- Collect day 90 immune deficiency panel IMDFP Tregs  
 
4. Day 180 study visit  
- Capture acute and chronic GVHD data, day 180 disease response  assessment and donor 
chimerism, mortality events  
- Capture time of sirolimus discontinuation  
- monitor AE/SAE throughout observation period  
- Collect day [ADDRESS_637863] day 180 research blood sample and bone marrow sample  
 
5. 1 year and 18 months  study visit s 
- capture chronic GVHD data, response assessment and donor  chimerism, mortality  
 
Pre-BMT work -up evaluations should be completed prior to initiation of conditioning 
chemotherapy within the screening windows defined in the table below. Evaluations done as a “standard of care” prior to consent on trial may be used for the trial screening if falling within the 
appropriate window from initiation of conditioning chemotherapy.  
 
Scheduled evaluations after screening and until engraftment may be performed +/ -3 days from 
the targeted date; assessments performed after engraftment and through Day 90 may be done 
+/-10 days of the targeted date.  After Day 90 assessments may be done +/ - [ADDRESS_637864] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  31 Activity  Pre-BMT  
Work -Up Day 1 To 
Engraftment1 Follow -Up Days 
42-90 Follow -Up ( >Day 90 
through Day 540)  
Consent  No Window     
Medical History  Within 30 days  Daily  weekly  X (day 180, 360, 540)  
Physical Exam  Within 30 days  Daily  weekly  X (day 180, 360, 540)  
RT consultation  No Window     
Karnofsky/Lansky  Within 30 days   day 90  X (day 180, 360, 540)  
GVHD Assessment   weekly start day 7  weekly, day 90  X (day 180, 360, 540)  
CBC/diff/plt  Within 30 days  Daily  weekly  X (day 180, 360, 540)  
PT/INR  Within 60 days     
Viral Screen  Within 60 days     
PRA (Donor Specific 
Antibody)  Within 60 days     
Basic metabolic panel   Daily    
Comprehensive 
metabolic panel  Within 30 days  2x/wk  weekly  X (day 180, 360, 540)  
eGFR for adults with creat > 1.[ADDRESS_637865] ( females 
of childbearing potential)  Within 30 days     
BM Biopsy  Within 60 days  X (day 30 ) X (day 90)  X (day 180, 360, 540)  
BM chimerism   BM (day 30)  BM (day 90)  BM (day 180, 360, 
540) 
Blood chimerism    PB (day 30)  PB (day 9 0) PB (day 180, 360, 
540) 
PETCT (lymphoma 
only)  Within 60 days    X 
Minimal Residual Disease  Within 60 days  BM (day 30)  BM (day 90)  BM (day 180, 360, 
540) 
T-Cell Immune 
Reconstitution Panel  Within 60 days  PB (day 30)  PB (day 90)  PB (day 180, 360, 
540) 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  32 Activity  Pre-BMT  
Work -Up Day 1 To 
Engraftment1 Follow -Up Days 
42-90 Follow -Up ( >Day 90 
through Day 540)  
CMV PCR (blood)   Weekly  Weekly   
HHV6 PCR (blood)   Weekly  Weekly   
PFT/DLCO  Within [ADDRESS_637866]/Sinus  Within 60 days     
Disease Evaluation  Within 60 days  X (day 30 ) X (day 90)  X (day 180, 360, 540)  
Research Bone 
Marrow and Blood 
Sample2 No Window  X (day 30 )   X (day 180)  
Blood samples for 
MMF   X (day 7 )3   
 
1 Engraftment defined as absolute neutrophil count (ANC) ≥ 5 X 108/L for 3 consecutive measurements  
2 Research blood samples will be used for cyclophosphamide genomics studies. Research blood samples will be 
collected in EDTA blood collection tubes  and research marrow samples will be collected in sodium heparin 
tubes . Excess blood and marrow samples  from existing samples  (including those collected for MCC [ZIP_CODE])  may 
be stored for future correlative studies  in lieu of collecting a new sample.  
3 Blood for MMF pharmacokinetic s tudies will be obtained on day 7  at the following time points: pre- dose, post -
dose, 1 hour, 2 hour, 4 hour, and 8 hours after dose in EDTA blood collection tubes.  Collections may occur +/ - 
10 minutes from the scheduled interval.  
 
NOTE: Patients with a history of MDS or a history of 2 or more consecutive inductions/re- inductions 
to treat acute leukemia or CML blast crisis or prolonged neutropenia of at least [ADDRESS_637867]  to exclude occult fungal infection prior 
to transplant.  
NOTE: In certain clinical circumstances (e.g. relapsed or terminally ill patients , risk of undue harm to 
patients, etc. ) study tests may be omitted at the physician’s discretion. Additionally,  tests may be 
rescheduled as clinically indicated.  
 
8.[ADDRESS_637868] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  33  
 
 
 
8.3 BIOMARKER, CORRELATIVE, AND SPECIAL STUDIES OR OTHER 
ENDPOINTS  
 
 
Specimen Type  Baseline (Pre -
treatment)  Day 7 Day 30  Day 180  
Cyclophosphamide Genomics 
(EDTA blood sample s) X    
Mycophophenolate 
pharmacokinetics ( EDTA blood 
samples)   X   
Blood and marrow for future 
studies  (EDTA tubes  for blood, 
heparin tubes for marrow )* X  X X 
*Blood and marrow samples for future studies may be added on to previously collecte d (off -trial) samples 
and/or research samples from other protocols (including MCC [ZIP_CODE]) if excess sample is available.      
8.3.1  MYCOPHENOLATE PHARMACOKINETICS  
Blood samples for the determination of Mycophenolate mofetil (MMF) and Mycophenolic Acid 
(MPA) concentrations will be collected in the study.  Free and total drug will be determined for 
both. The actual PK sampling times should be recorded accurately in the PK requisition forms.  
Measurements will be taken on post -transplant  day 7 at pre -dose and then at the end of the 
infusion, followed by 1, 2, 4, 8 hours after the end of infusion.  Collections may occur +/ - [ADDRESS_637869] es are not collected on day 7 (e.g., due to day 7 falling 
on a holiday or weekend), then samples may be collected within 3 days of day 7 (days 8, 9, or 10). 
MMF PK samples should NOT be collected prior to day 7.   
a. Pharmacokinetic Blood Sample Collection and Handling  
At each specified time point, a single [ADDRESS_637870] blood.  
Vacutainers will be kept on crushed ice after blood collection. Within 30 minutes, the tubes will be centrifuged for 5 minutes at 1100 x g at 4°C to separate the plasma.   After centrifugation, 
plasma will be transferred into polypropylene screw -cap tubes labeled appropriately for total drug 
assays of MMF and MPA.  Remaining plasma will be added to specialty centrifuge devices to create free- fractionate of drug.  These ali quots will be assayed for free concentrations of each 
drug.  All samples will be stored at of -80ºC until analysis.   
Day MMF/MPA PK [ADDRESS_637871] for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637872] +/ -[ADDRESS_637873] +/ -[ADDRESS_637874] +/ -[ADDRESS_637875] +/ -10 min 
 
1. All collection time points after administration are relative to the end of infusion, regardless 
of length of administration and dosage.  
b. Analytical Methods  
Concentrations of MMF and MPA will be determined by [CONTACT_496234]/MS/MS methods that have been validated according to ICH/FDA 
guidelines for bio- analytical analysis.  
8.3.2  CYCLOPHOSPHAMIDE PHARMACOGENOMICS  
In order to assess the presence of single nucleotide polymorphisms (SNPs) in [ADDRESS_637876] 
that influence drug metabolism ( CYP2B6, CYP2C19,  CYP2C9,  CYP3A5,  GSTP1, ALDH1A1) , 
targeted sequencing will be performed using a Qiagen QiaSeq Pharmacogenomics Panel.   Qiagen 
QiaSeq panels incorporate unique molecular indices (UMIs) which facilitate accurate variant allele 
frequency reporting while also reducing the number of artefactual variants.   Briefly, the sample 
DNA will be enzymatically fragmented, followed by [CONTACT_496235]- repair, A -addition, and adaptor 
ligation. Target enrichment with locus -specific primers and library amplification will be performed, 
and the final libraries will be screened on an Agilent TapeStation (Agilent Technologies, Inc., Santa 
Clara, CA) and quantitated by [CONTACT_496236] ([COMPANY_002] Diagnostics, 
U.S., Indianapolis, IN).   The indexed samples will be sequenced on the NextSeq 500 sequencer 
(Illumina, Inc. San Diego, CA) with150 -base paired- end reads.   Data analysis including alignment 
and variant calling will be performed using the QiaSeq data analysis pi[INVESTIGATOR_19189].  
 
8.4 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS  
 
8.4.1 DEFINITION OF ADVERSE EVENTS (AE)  
 
An adverse  event  is any unexpected  medical  occurrence  associated with the use of a drug or 
therapy  in humans,  whether  or not considered  drug related.  It can be any unfavorable and 
unintended sign (e.g.,  an abnormal  laboratory  finding),  symptom,  or disease,  temporally  
associated with the use of a drug.  Infection,  acute and chronic  GVHD will not be considered  
adverse events.  
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  35  
 
8.4.2 DEFINITION OF SERIOUS ADVERSE EVENTS (SAE)  
 
An adverse event or suspected adverse reaction is considered "serious" if, in the view of either the 
investigator or sponsor, it results in any of the following outcomes:  
• death,  
• a life -threatening adverse event,  
• inpatient hospi[INVESTIGATOR_1081],  
• a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or  
• a congenital anomaly/birth defect.  
Important medical events that may not result in death, be life -threatening, or require hospi[INVESTIGATOR_6721], based upon appropriate medical judgment, they may jeopardize 
the patient or subject and may require medical or surgical i ntervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include allergic bronchospasm 
requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions 
that do not result in inpatient hospi[INVESTIGATOR_059], or the development of  drug dependency or drug 
abuse.  
 
 
8.4.3 CLASSIFICATION OF AN ADVERSE E VENT  
 
[IP_ADDRESS]  SEVERITY OF EVENT  
 
Toxicity and adverse events will be classified according to NCI's Common Terminology 
Criteria for Adverse Events V 5.0  (CTCAE).  A copy of the CTCAE can be downloaded 
from the CTEP home page http://evs.nci.nih.gov/ftp1/CTCAE/About.html    
[IP_ADDRESS]  EVENT DOCUMENTATION  
Transplant related outcomes and events will be recorded in the Blood and Marrow 
Transplantation (BMT) database.   
Events requiring prompt reporting to the Moffitt Cancer Center Protocol Monitoring 
Committee, the Institutional Review Board (IRB), early stoppi[INVESTIGATOR_319526], and protocol 
deviations will be documented in OnCore.  
[IP_ADDRESS]  RELATIONSHIP TO STUDY INTERVENTION  
 
Anticipated toxicity following allogeneic transplantation:  
There are numerous anticipated adverse consequences of transplantation, which include, but are 
not limited to conditioning regimen related toxicity such as severe mucositis, cytokine release 
syndrome, idiopathic pneumonia syndrome, hepatic veno- occlusive disease and death, early and 
late infectious complications, potentially severe or fatal acute or chronic graft vs. host disease, 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637877] -transplantation toxicity.  
Adverse event recording:  
Non-serious AE: Only unexpected, grade 3 -5 AE will be recorded.  
Serious AE: All SAE will be recorded.  
Adverse event reporting:  
Non-serious AE: Unexpected, grade 3- 5 AE will be reported to the IRB in summary form on an 
annual basis.  
[IP_ADDRESS]  EXPECTEDNESS  
 
The PI [INVESTIGATOR_118631]. An AE will 
be considered unexpected if the nature, severity, or frequency of the event is not consistent with 
the risk information previously  described for the study agent.  
  
8.4.4 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND 
FOLLOW -UP 
 
The occurrence of an adverse event (AE) or serious adverse event (SAE) may come to the 
attention of study personnel during study visits and interviews of a study participant presenting 
for medical care, or upon review by a study monitor.  
 
Adverse events can be spontaneously reported or elicited during open -ended questioning, 
examination, or evaluation of a patient.  
 
All AEs, including local and systemic reactions not meeting the criteria for SAEs, will be captured 
on the appropriate case report form (CRF). Information to be collected will include event 
description, time of onset, clinician’s assessment of severity, relationship to study product 
(assessed only by [CONTACT_8703] a diagnosis), and time of 
resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship. All A Es will be followed to adequate resolution.  
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  37 Any medical condition that is present at the time that the participant is screened will be 
considered as baseline and not reported as an AE. However, if the study participant’s condition 
deteriorates at any time during the study, it will be recorded as an AE.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of 
the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each epi[INVESTIGATOR_1865].  
 
All events beginning with start of study intervention until [ADDRESS_637878] day of study 
intervention will be reported. At each study visit, the investigator will inquire about the occurrence 
of AE/SAEs since the last visit. Events will be followed for outcome information unt il resolution or 
stabilization.  
 
8.4.5 ADVERSE EVENT REPORTING  
 
Grade 3 or higher unexpected AEDs  will be recorded from initiation of conditioning 
chemother apy through day +90 after transplant infusion  at each examination on the Adverse 
Even t case report forms/worksheets.  
 
8.4.6 SERIOUS ADVERSE EVENT REPORTING  
 
The principal investigator [INVESTIGATOR_496206], regardless attribution,  within 24 
hours of learning of the occurrence. In the event that the principal investigator [INVESTIGATOR_496207] (e.g., participant sought treatment  elsewhere), 
the principal investigator [INVESTIGATOR_496208] [ADDRESS_637879]  include event 
term(s), serious criteria, and the investigator’s determination of both the intensity  of the event(s) 
and the relationship o f the event(s) to study drug administration.  
 
8.4.[ADDRESS_637880]  
 
Not applicable 
 
8.4.9 REPORTING OF PREGNANCY  
 
Pregnancy, although not itself a serious adverse event, should also be reported and be followed 
up to determine outcome, including spontaneous or voluntary termination, details of birth, and the presence or absence of any birth defec ts or congenital abnormalities.  
 
8.5 UNANTICIPATED PROBLEMS  
 
8.5.1 DEFINITION OF U NANTICIPATED PROBLEMS (UP)  
 
The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving 
risks to participants or others to include, in general, any incident, experience, or outcome that 
meets all of the following criteria:  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  38  
• Unexpected in terms of nature, severity, or frequency given (a) the research procedures 
that are described in the protocol -related documents, such as the Institutional Review 
Board ( IRB)-approved research protocol and informed consent document; and (b) the 
characteristics of the participant population being studied;  
• Related or possibly related to participation in the research (“possibly related” means there 
is a reasonable possibility that the incident, experience, or outcome may have been 
caused by [CONTACT_3459]); and  
• Suggests that the research places participants or others at a greater risk of harm 
(including physical, psychological, economic, or social harm) than was previously known 
or recognized. ] 
 
 
8.5.2  UNANTICIPATED PROBLEM REPORTING  
  
The investigator will report unanticipated problems (UPs) to the reviewing Institutional Review 
Board (IRB) and to the Moffitt Cancer Center  Protocol Monitoring Committee. The UP report will 
include the following information:  
 
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome represents an UP;  
• A description of any changes to the protocol or other corrective actions that have been 
taken or are proposed in response to the UP.  
 To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:   
 
• UPs that are serious adverse events (SAEs) will be reported to the IRB within 24 hours  of 
the investigator becoming aware of the event.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting procedures), the supporting agency head (or designee), and 
the Office for Human Research Protections (OHRP) within 7 days  of the IRB’s receipt of 
the report of the problem from the investigator.  
  
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  39  
 
9 STATISTICAL CONSIDERATIONS   
 
9.1 STATISTICAL ENDPOINTS  
 
Primary Endpoint: The primary endpoint is the probability of disease -free 
survival (DFS) by 1.[ADDRESS_637881] -transplant.  An event will be defined as 
death or a relapse . 
Secondary Endpoints:  
• Probability of Grade II -IV and Grade III -IV aGVHD at 180 days  
• Probability of TRM at 6 months and 18 months   
• Probability of relapse at  18 months  
• Probability of OS at 18 months  
Transplant Related Endpoints  
• Probability of neutrophil recovery by [CONTACT_4475] +30  
• Probability of platelet recovery by [CONTACT_4475] +60  
• Proportion of donor cell engraftment (chimerism) at days + 30, +60, + 90, 
+180 and +365  
• Probability of 18 months  chronic GVHD  
• Probability of 18 months  overall GVHD  
• Probability of 18 months  GRFS  
• Probability of serious fungal and viral infections at day +[ADDRESS_637882] 
 
 
9.2 SAMPLE SIZE DETERMINATION  
 
The primary endpoint of this study is disease- free survival  (DFS) . The historic DFS at 18 months  
is 40%. [67-69] We assume that the DFS at 18 months  in patients treated with Flu/TBI and low 
dose Mel will be 60%, corresponding to a hazard ratio (HR) of 0.557. A total of [ADDRESS_637883] 90.2% power to detect a HR of 0.[ADDRESS_637884] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  40  
9.3 STATISTICAL ANALYSES  
 
9.3.1 GENERAL APPROACH 
 
The final analysis for the primary endpoint will be conducted when 18 events are observed. The 
time-to-event endpoint will be analyzed by [CONTACT_33480]- Meier  (KM)  method as the primary 
analytic tool. The association with time- to-event endpoint will be explored by [CONTACT_496237]. If the competing risk exists, the competing risk approach and Fine- Gray regression model will be used.  
Cumulative incidence will be used to estimate the probabilities of GVHD, relapse, infection, and neutrophil and platelet recovery treating deaths as a competing risk. For GVHD endpoint, relapse 
and death will serve as the competing risks. The Gray test will be used accordingly. The probability 
of TRM will be estimated in a similar manner but treating relapse as a  competing risk.  
Ninety -five percent confidence intervals will be estimated from respective standard errors  and the 
complementary log- log transformation. The proportion of donor chimerism (classified as ≥70% 
donor cells at various time- points will be estimated among patients who have survived to the 
evaluated time-point). Descriptive plots and measures will also be used to evaluate chimerism as 
a continuous measure. Medians, ranges and inter -quartile ranges will be given for actual 
chimerism values. Analyses will be performed and plots generated using SAS 9.3 ( SAS Institute, 
Cary, NC) and/or R 3.0.2.   
 
9.3.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT  
 
The disease- free survival  (DFS)  is defined as the time from the date of PBSCT to first 
documentation of relapse or death due to any cause, whichever comes first. Patients  who do not 
relapse and are still on the study at the time of an analysis, will be censored at the date of the 
last disease assessment documenting absence of relapse. The final statistical analysis will be 
conducted when 18 events (deaths or relapses) are observed . The Kaplan- Meier (KM) method 
and complementary log -log transformation will b e used to estimate the DFS and the associated 
confidence interval. If the lower limit of one- sided 90% confidence interval at 18 months is 
greater than 40%, then the null hypothesis will be reject ed. As a secondary approach, the Cox 
proportional hazard regression model will be used to explore the association with covariates .    
 
9.3.3 ANALYSIS OF THE SECONDARY ENDPOINTS  
  
Overall survival (OS) is defined as the time from the date of PBSCT to the date of death due to 
any cause. OS will be censored at the last date the patient  is known to be alive. The GVHD -
free/relapse- free survival (GRFS) is defined as the time from the date of PBSCT to date of 
events which include grade 3- [ADDRESS_637885]. OS , GRFS,  and 95% confidence interval will be computed by 
[CONTACT_496238]- log transformation. The cumulative incidence of acute 
GVHD, relapse, and treatment -related mortality will be estimated by [CONTACT_496239] -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637886] using the concentration at each 
sampling time. PhoenixTM WinNonlin® ver 8.1 (www.Pharsight.com) will be used for the 
pharmacokinetic calculations. The maximum measured concentration, C max, and its associated 
time will be used as the C max, and T max values for each subject.  The area under the plasma 
concentration curve from time zero to the time of the last measurable concentration (AUC 0-t) and 
from time zero to infinity (AUC 0-∞) will be calculated where applicable. The elimination rate 
constant (k e) clearance (CL), and volume of distribution (V z) calculated from the terminal 
elimination phase will also be calculated where applicable. The elimination rate constant will be converted to the terminal half -life, t
1/2, (t1/2 = ln2/k e). The reliability of the pharmacokinetic 
parameters will be determined using the correlation coefficient, r2, for the fit of the elimination 
constant to the terminal data points. Data with good fits are characterized by r2 > 0.9. Subjects 
will be dichotomized by [CONTACT_496240] (i.e., ≤  median vs. > median). The incidence of 
acute GVHD by [CONTACT_496241]. The 
association with the incidence of acute GVHD will be explored by [CONTACT_496242]- Gray regression 
model. No multiplicity adjustment is considered.  Correlations with clinical endpoints may be 
pursued.  
9.3.5 CYCLOPHOSPHAMIDE PHARMACO GENETIC ANALYSES  
The single nucleotide polymorphisms (SNPs) in the 6 genes ( CYP2B6, 
CYP2C19,  CYP2C9,  CYP3A5,  GSTP1, ALDH1A1) known to impact cyclophosphamide 
metabolism will be analyzed by [CONTACT_496243]. The incidence of acute GVHD 
by [CONTACT_496244]. The association with the incidence of 
acute GVHD will be explored by [CONTACT_496245]-Gray regression model. No multiplicity adjustment is 
considered.  Correlations with clinical endpoints may be pursued.  
9.3.[ADDRESS_637887] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  42  
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  
 
 
10.1 REGULATORY, ETHICA L, AND S TUDY OVERSIGHT CONSIDERATIONS  
10.1.1  SCIENTIFIC REVIEW COMMITTEE (SRC)  
The Cancer Center’s internal SRC provides the review for scientific merit and prioritization and 
monitors scientific progress for all protocols at the Cancer Center. The SRC has a defined 
membership representing all of the major research divisions of the c ancer center, including 
biostatisticians. The SRC reviews newly proposed clinical research studies based on the following 
categories:  
a. study significance to evaluate its potential for contribution to medical science.  
b. the adequacy of study objectives, design, specific aims and hypotheses.  
c. the methods to be employed to conduct the study. Ensuri ng that the study is adequately 
described, including inclusion/exclusion criteria, sample size, procedures and instruments to be 
used.  
d. Feasibility of the study. Ensuring the investigator has adequate staffing and facilities to conduct 
the study. Ensuring that the timeframe for the study and projected annual accrual are adequately 
addressed.  
e. Review of all data and safety monitoring plans.  
The SRC will also evaluate the risk/benefit assessment and corresponding Data & Safety Monitoring Plan (DSMP), evaluate and may recommend frequency of monitoring. The SRC will 
identify any potential conflicts of interest related to the proposed research. The SRC may also 
evaluate and recommend the monitoring frequency of clinical trials they approve.  
 
10.1.2 THE PROTOCOL MONITORING COMMITTEE (PMC)  
The Protocol Monitoring Committee (PMC) is a multidisciplinary, peer review, standing committee established to oversee clinical research conducted at Moffitt Cancer Center to monitor scientific 
progress and data quality. It also serves as a component of the Data Safety Monitoring Plan 
(DSMP) for oncology trials at MCC. The membership of the PMC includes physicians and scientists 
from various program areas.  
The PMC provides ongoing monitoring of all clinical research studies for safety, validity and integrity of data, adverse events, conflicts of interest, and overall compliance with GCP or other 
applicable clinical research guidelines or regulations. In addi tion to the protocol stoppi[INVESTIGATOR_004], the 
PMC is authorized to suspend a trial for non- compliance with a DSMP or as a result of audit 
findings deemed unacceptable.  
 
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637888] (IRB) approved protocol,  Center’s 
policies, Good Clinical Practices ( GCP): Consolidated Guidance, and applicable regulatory 
requirements.  
Audits are conducted by [CONTACT_496246]. Corporate Compliance will conduct and report the findings of audits to the PMC.  
The PMC will determine the findings to be: acceptable, acceptable with corrective action, or unacceptable. Corporate Compliance will follow up to ascertain whether corrective actions, which  
have been agreed to, are achieving the desired results. The PMC will be informed of all significant open follow -up items. For those observations where no action has been taken, Corporate 
Compliance will inform the PMC who may take action as appropriate.  
10.1.4 INTERNAL MONITORING  
Monitoring will be performed regularly by [CONTACT_490693], 
completeness, and source verification of data entry, validation of appropriate informed consent 
process, reporting of SAEs, and adherence to the protocol, Good Clinical Practice(GCP) 
guidelines, and applicable regulatory requirements.  
10.1.[ADDRESS_637889] (IRB)  
The trial will not be initiated without approval of the appropriate Institutional Review Board (IRB). All administrative requirements of the governing body of the institution will be fully complied with. 
This protocol, consent procedures, and any amendment s will be approved by [CONTACT_490694]; in which case, the IRB will be notified 
within 24 hours of implementing the change.  
The IRB will be kept informed by [CONTACT_496247].  
10.1.6 INFORMED CONSENT PROCESS  
 
10.1.7 CONSENT/ASSENT AND OTHER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANTS  
 
Consent forms describing in detail the study intervention, study procedures, and risks are given to 
the participant and written documentation of informed consent is required prior to starting 
intervention/administering study intervention.   
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  44 10.1.8 CONSENT PROCEDURES AND DOCUMENTATION  
 
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Consent forms will be 
Institutional Review Board (IRB) -approved and the participant will be asked to read and review the 
document.  
 
The investigator will explain the research study to the participant and answer any questions that 
may arise. A verbal explanation will be provided in terms suited to the participant’s comprehension 
of the purposes, procedures, and potential risks of the st udy and of their rights as research 
participants.  
 
Participants will have the opportunity to carefully review the written consent form and ask questions 
prior to signing. The participants should have the opportunity to discuss the study with their family 
or surrogates or think about it prior to agreeing to  participate. The participant will sign the informed 
consent document prior to any procedures being done specifically for the study.  
 
Participants must be informed that participation is voluntary and that they may withdraw from the 
study at any time, without prejudice. A copy of the informed consent document will be given to the 
participants for their records. The informed consent proces s will be conducted and documented in 
the source document (including the date), and the form signed, before the participant undergoes 
any study -specific procedures. The rights and welfare of the participants will be protected by 
[CONTACT_34693].  
 
  
 
10.2 STUDY DISCONTINUATION AND CLOSURE  
 
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause.  Written notification, documenting the reason for study suspension or 
termination, will be provided by [CONTACT_61188], investigator, funding 
agency, the Investigational New Drug ( IND) or Investigational Device Exemption ( IDE) sponsor 
and regulatory authorities.  If the study is prematurely terminated or suspended, the Principal 
Investigator ( PI) will promptly inform study participants, the Instituti onal Review Board ( IRB), and 
sponsor and will provide the reason(s) for the termination or suspension.  Study participants will be 
contact[INVESTIGATOR_530], as applicable, and be informed of changes to study visit schedule.  
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stoppi[INVESTIGATOR_007]   
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable 
• Determination that the primary endpoint has been met  
• Determination of futility  
 Study may resume once concerns about safety, protocol compliance, and data quality are 
addressed,  and satisfy the sponsor, IRB and/or Food and Drug Administration ( FDA). 
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  45 10.2.1 TOXICITY MONITORING AND STOPPI[INVESTIGATOR_496209], graft failure, and relapse rate. The tables below 
show the stoppi[INVESTIGATOR_496210] (T n), graft failure (G n), and Relapse (R n), for a given number of 
patients up to that point. The trial will be halted if at least one of the stoppi[INVESTIGATOR_496211], and 
the data will be reviewed by [CONTACT_429803]. This is a Pocock -
type stoppi[INVESTIGATOR_496212]. that yields the probability of crossing the boundary at 
most 10% if  
• TRM rate at day 100 is ≤30%, 
• graft failure rate at day 100 is ≤ 20%,  
• relapse rate at day 100 is ≤ 30%.  
For example, if 2 TRMs are observed in 3 patients, the trial will be halted due to the excessive TRM. Table 
2 contains the probability of early stoppi[INVESTIGATOR_496213], graft failure, and relapse rates. If the true 
TRM  rate, for example,  is unacceptably high (30%), the stoppi[INVESTIGATOR_496214] 92 % probability of 
early stoppi[INVESTIGATOR_007].  
 
Table 1: Early Stoppi[INVESTIGATOR_496215] (T n), graft failure (G n), and Relapse (R n) 
Number of 
Patients,  n Stoppi[INVESTIGATOR_496216],  n Stoppi[INVESTIGATOR_496217] 
[ADDRESS_637890] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  46  
Table 2: Probability of early stoppi[INVESTIGATOR_496213], graft failure, and relapse rates  
Ture TRM 
rate Prob ability  of 
Early Stoppi[INVESTIGATOR_496218]  
0.3 0.0984  0.2 0.0986  0.3 0.0984  
0.4 0.392  0.3 0.454  0.4 0.392  
0.5 0.7867  0.4 0.8437  0.5 0.7867  
0.6 0.9721  0.5 0.9825  0.6 0.9721  
0.7 0.9991  0.6 0.9995  0.7 0.9991  
0.8 1 0.7 1 0.8 1 
0.9 1 0.8 1 0.9 1 
1 1 0.9 1 1 1 
 
 
 
10.3 FUTURE USE OF STORED SPECIMENS AND DATA  
 
Data collected for this study will be analyzed and stored at the Moffitt Cancer Center. With the 
participant’s approval and as approved by [CONTACT_141238] (IRBs), de -identified 
biological samples will be stored at the Moffitt Cancer Center . These samples could be used to 
research the causes of hematologic malignancies and/or post -transplant outcomes. The Moffitt 
Cancer Center will also be provided with a code -link that will allow linking the biological specimens 
with the phenotypic data from each participant, maintaining the blinding of the identity of the 
participant.  
 
During the conduct of the study, an individual participant can choose to withdraw consent to have 
biological specimens stored for future research. However, withdrawal of consent with regard to 
biosample storage may not be possible after the study is completed.  
 
 
10.3.[ADDRESS_637891]  
Tampa, FL [ZIP_CODE]  
[PHONE_10307]  
Nelli.Bej [EMAIL_9488]    
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  47 10.3.2 SAFETY OVERSIGHT  
 
Serious Adverse Events: Serious Adverse Events (SAEs) from this protocol will be reported 
concurrently to the IRB and the study sponsor. The Protocol Monitoring Committee (PMC) will 
review these SAEs in accordance with the protocol -specific DSMP. The data and safety plan will 
define dose limiting toxicities, rules for escalation of dose, and criteria for stoppi[INVESTIGATOR_312655] (MTD) according to rules set forth by [CONTACT_3181]. This trial 
will be continuously monitored by [CONTACT_978] [INVESTIGATOR_496219]. This protocol will be subject to periodic internal audits based on ris k or 
as recommended by [CONTACT_428360].  
 
 
10.3.3 CLINICAL MONITORING  
 
MCC’s  Internal Monitors will periodically monitor regulatory documents and case report forms 
according to the protocol specific clinical monitoring plan.  Monitoring will include review of data 
for accuracy, completeness, and source verification, reporting of S AEs, and adherence to the 
protocol, Good Clinical Practice (GCP) guidelines, and appl icable regulatory requirements.  
 
10.3.[ADDRESS_637892], data and biological 
specimen collection, documentation and completion.  An individualized quality management plan 
will be developed to describe a site’s quality management.]  
 
Quality control (QC) procedures will be implemented beginning with the data entry system and 
data QC checks that will be run on the database will be generated. Any missing data or data 
anomalies will be communicated to the site(s) for clarification/resolut ion. 
 Following written Standard Operating Procedures (SOPs), the monitors will verify that the clinical 
trial is conducted and data are generated and biological specimens are collected, documented 
(recorded), and reported in compliance with the protocol, International Conference on 
Harmonization  Good Clinical Practice (ICH GCP), and applicable regulatory requirements (e.g., 
Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
 
The investigational site will provide direct access to all trial related sites, source data/documents, and reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_21229].  
 
 
10.3.[ADDRESS_637893]  KEEPI[INVESTIGATOR_1645]   
 
10.3.6 DATA COLLECTION AND  MANAGEMENT RESPONSIBILITIES  
 
The Principal Investigator [INVESTIGATOR_490656](s) assigned to the case will be primarily 
responsible for maintaining all study related documents including clinical research forms, as 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637894] for all CRF entries and will be verified with source 
documentation. The review of medical records within PowerChart will be done in a manner to 
assure that patient confidentiality is maintained.  
 
Data collected will be stored in Moffitt Cancer Center’s database system, ONCORE. Identifying 
patient information will be kept confidential. Representatives of the IRB and the FDA will have 
access to patient information as it pertains to the study. Privacy and confidentiality of the 
information will be protected to the extent provided by [CONTACT_2371] . 
 
10.3.7 STUDY RECORDS RETENTION  
The study will be conducted in accordance with the appropriate regulatory requirement(s).  
Essential clinical documents will be maintained to demonstrate the validity of the study and the 
integrity of the data collected.  Master files should be established at the beginning of the study, 
maintained for the duration of the study and retained according to the appropriate regulations.   
10.3.8 PROTOCOL DEVIATIONS  
 
A protocol deviation is any noncompliance with the clinical trial protocol, GCP, or MOP 
requirements. The noncompliance may be either on the part of the participant, the investigator, or 
the study site staff. As a result of deviations, corrective actions are to be developed by [CONTACT_90478].  
These practices are consistent with ICH E6:  
 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.[ADDRESS_637895] be sent to the local IRB per their 
guidelines. The site PI/study staff is responsible for knowing and adhering to their IRB 
requirements.  
 
10.3.9 PUBLICATION AND DATA SHARING POLICY  
 
This study will be conducted in accordance with the following  publication and data sharing  policies 
and regulations:  
 National Institutes of Health ( NIH) Public Access Policy, which ensures that the public has access 
to the published results of NIH funded research. It requires scientists to submit final peer -reviewed 
journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon 
acceptance for publication.  
 
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -
Funded Clinical Trial Information and the Clinical Trials Registration and Results Information 
Submission r ule. As such,  this trial will be  registered at ClinicalTrials.gov, and results information 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637896] ed from other 
researchers x years after the completion of the primary endpoint by [CONTACT_13172] <specify person or 
awardee institution, or name [CONTACT_496251] >.  
 
In addition, this study will comply with the NIH Genomic Data Sharing Policy , which  applies to all 
NIH-funded research that generates large- scale human or non- human genomic data, as well as 
the use of these data for subsequent research. Large- scale data include genome- wide association 
studies (GWAS), single nucleotide polymorphisms (SNP)  arrays, and genome sequence, 
transcriptomic, epi[INVESTIGATOR_141214], and gene expression data . 
 
10.3.[ADDRESS_637897] for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637898]  
IB Investigator’s Brochure  
ICH International Conference on Harmonization  
ICH E6  International Conference on Harmonization  Guidance for Industry, Good Clinical Practice: Consolidated 
Guidance  
ICMJE  International Committee of Medical Journal Editors  
IDE Investigational Device Exemption  
IND Investigational New Drug Application  
IRB Investigational Review Board  
ISO International Organization for Standardization  
MCC  Moffitt Cancer Center  
MedDRA  Medical Dictionary for Regulatory Activities  
MOP  Manual of Procedures  
MSDS  Material Safety Data Sheet  
NIH National Institutes of Health  
NIH IC  NIH Institute & Center  
OHRP  Office for Human Research Protections  
PI [INVESTIGATOR_496220] -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637899] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  52 11 REFERENCES  
 
1. 1. Grewal  SS, Barker  JN, Davies  SM, Wagner  JE. Unrelated  donor  hematopoietic  cell transplantation:  
marrow  or umbilical  cord  blood?  Blood.  2003;101(11):4233- 44. doi:10.1182/blood -2002 -08-2510.  
2. Confer  D, Robinett  P. The US National  Marrow  Donor  Program  role in unrelated  donor  hematopoietic  cell 
transplantation.  Bone  marrow  transplantation.  2008;[ADDRESS_637900]  1:S3 -S5.  
3. Ballen  KK, Spi[INVESTIGATOR_496221], Yeap  BY, McAfee S, Dey BR, Attar  E et al. Double  unrelated  reduced -intensity  umbilical  cord  
blood  transplantation  in adults.  Biology  of blood  and marrow  transplantation  : journal  of the American  Society  for 
Blood  and Marrow  Transplantation.  2007;13(1):82- 9. doi:10.1016/j.bbmt.2006.08.041.  
4. Barker  JN, Weisdorf DJ, DeFor  TE, Blazar  BR, Miller  JS, Wagner  JE. Rapid  and complete donor  chimerism  in adult  
recipi[INVESTIGATOR_496222] -intensity  conditioning.  Blood.  
2003;102(5):1915 -9. doi:10.1182/blood -2002- 11-3337.  
5. Brunstein CG, Barker  JN, Weisdorf DJ, DeFor  TE, Miller  JS, Blazar  BR et al. Umbilical  cord  blood  transplantation  
after  nonmyeloablative  conditioning:  impact  on transplantation  outcomes  in 110 adults  with  hematologic  disease.  
Blood.  2007;110(8):3064 -70.  
6. Gragert  L, Eapen  M, Williams  E, Freeman  J, Spellman  S, Baitty  R et al. HLA Match  Likelihoods  for Hematopoietic  
Stem -Cell Grafts  in the U.S. Registry.  NEJM.  2014;371:339- 48.  
7. Gladstone  DE, Zachary  AA, Fuchs  EJ, Luznik  L, Kasamon  YL, King KE et al. Partially  mismatched  transplantation  and 
human leukocyte  antigen  donor -specific  antibodies.  Biology  of blood  and marrow  transplantation  : journal  of the 
American  Society  for Blood  and Marrow  Transplantation.19(4):647- 52.  
8. Broxmeyer  H, Douglas  G, Hangoc  G, Cooper  S, Bard  J, English  D et al. Human  umbilical  cord  blood  as a potential  
source  of transplantable  hematopoietic  stem/progenitor  cells.  Proc  Natl  Acad  Sci [LOCATION_003].  1989;86(10):3828- 32.  
9. Szydlo  R, Goldman  J, Klein  J, Gale R, Ash R, Bach  F et al. Results  of allogeneic bone  marrow  transplants  for 
leukemia  using  donors  other  than  HLA-identical  siblings.  J Clin Oncol.  1997;15(5):1767- 77.  
10. Aversa  F, Tabilio  A, Velardi  A, Cunningham  I, Terenzi  A, Falzetti  F et al. Treatment  of high -risk acute  leukemia  
with  T-cell-depleted  stem cells  from related  donors  with  one fully  mismatched  HLA haplotype.  NEJM.  
1998;339(17):[ADDRESS_637901]  Blood  from Unrelated  Donors.  NEJM.  2001;344:1815- 22.  
12. Bolaños -Meade J, Fuchs  E, Luznik  L, Lanzkron  S, Gamper  C, Jones  R et al. HLA-haploidentical  bone  marrow  
transplantation  with  posttransplant  cyclophosphamide  expands  the donor  pool  for patients  with  sickle  cell disease.  
Blood.  2012;120:4285 -91.  
13. Bolaños -Meade J, Gamper  C, Cooke  K, Jones  R, Brodsky  R. Curative  Allogeneic Bone  Marrow  Transplantation  
(AlloBMT) for Severe Hemoglobinopathies  No Longer  Requires  Matched  Donors  or the Ability  to Tolerate  
Myeloablative  Conditioning.  ASBMT  Tandem  Conference.  2018.   
14. Chang  YJ, Xu LP, Liu DH, Liu KY, Han W, Chen  YH et al. The impact  of CD34+  cell dose  on platelet  engraftment  in 
pediatric patients  following unmanipulated haploidentical  blood  and marrow  transplantation.  Pediatr  Blood  Cancer.  
2009;53(6):1100- 6.  
15. Powles  RL, Morgenstern  GR, Kay HE, McElwain  TJ, Clink  HM,  Dady  PJ et al. Mismatched  family  donors  for bone -
marrow  transplantation  as treatment  for acute  leukaemia.  Lancet.  1983;1(8325):612 -5.  
16. Beatty  PG, Clift RA, Mickelson  EM, Nisperos  BB, Flournoy N, Martin  PJ et al. Marrow  transplantation  from 
related  donors  other  than  HLA-identical  siblings.  The New  England  journal  of medicine.  1985;313(13):765 -71. 
doi:10.1056/NEJM198509263131301.  
17. Szydlo  R, Goldman  JM, Klein  JP, Gale RP, Ash RC, Bach  FH et al. Results  of allogeneic bone  marrow  transplants  
for leukemia  using  donors  other  than  HLA-identical  siblings.  Journal  of clinical  oncology  : official  journal  of the 
American  Society  of Clinical  Oncology.  1997;15(5):1767- 77.  
18. Chang  YJ, Xu LP, Liu DH, Liu KY, Han W, Chen  YH et al. Platelet  engraftment  in patients  with  hematologic 
malignancies  following unmanipulated haploidentical  blood  and marrow  transplantation:  effects  of CD34+  cell dose  
and disease  status.  Biol Blood  Marrow  Transplant.  2009;15(5):632- 8.  
19. Ciceri  F, Labopin  M, Aversa  F, Rowe JM, Bunjes  D, Lewalle P et al. A survey  of fully  haploidentical  hematopoietic  
stem cell transplantation  in adults  with  high -risk acute  leukemia:  a risk factor  analysis  of outcomes  for patients  in 
remission  at transplantation.  Blood.  2008;112(9):[ADDRESS_637902] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  53 20. Federmann  B, Bornhauser  M, Meisner  C, Kordelas  L, Beelen  DW,  Stuhler  G et al. Haploidentical  allogeneic 
hematopoietic  cell transplantation  in adults  using  CD3/CD19 depletion  and reduced  intensity  conditioning:  a phase  
II study.  Haematologica.97(10):1523- 31.  
21. Godder  KT, Henslee -Downey  PJ, Mehta  J, Park  BS, Chiang  KY, Abhyankar  S et al. Long  term disease -free survival  
in acute  leukemia  patients  recovering  with  increased  gammadelta  T cells  after  partially  mismatched  related  donor  
bone  marrow  transplantation.  Bone  marrow  transplantation.  2007;39(12):751- 7.  
22. Federmann  B, Hagele  M, Pfeiffer  M, Wirths  S, Schumm  M, Faul  C et al. Immune reconstitution  after  
haploidentical  hematopoietic  cell transplantation:  impact  of reduced  intensity  conditioning and CD3/CD19 depleted  
grafts.  Leukemia.25(1):121- 9.  
23. Munchel  A, Kesserwan  C, Symons  HJ, Luznik  L, Kasamon  YL, Jones  RJ et al. Nonmyeloablative,  HLA-haploidentical  
bone  marrow  transplantation  with  high  dose,  post -transplantation  cyclophosphamide.  Pediatr  Rep.[ADDRESS_637903]  2:e15.   
24. Ciurea  SO, Mulanovich  V, Saliba  RM, Bayraktar  UD, Jiang Y, Bassett  R et al. Improved  early  outcomes  using  a T 
cell replete graft  compared  with  T cell depleted  haploidentical  hematopoietic  stem  cell transplantation.  Biology  of 
blood  and marrow  transplantation  : journal  of the American  Society  for Blood  and Marrow  
Transplantation.18(12):1835 -44.  
25. Raiola  AM, Dominietto  A, Ghiso  A, Di Grazia C, Lamparelli  T, Gualandi  F et al. Unmanipulated haploidentical  
bone  marrow  transplantation  and posttransplantation  cyclophosphamide  for hematologic  malignancies  after  
myeloablative  conditioning.  Biology  of blood  and marrow  transplantation  : journal  of the American  Society  for 
Blood  and Marrow  Transplantation.19(1):[ADDRESS_637904] -transplantation  cyclophosphamide  results  
in outcomes  equivalent  to those  of contemporaneous  HLA-matched  related  and unrelated donor  transplantation.  
Journal  of clinical  oncology  : official  journal  of the American  Society  of Clinical  Oncology.31(10):1310- 6.  
27. Solomon  SR, Sizemore CA, Sanacore  M, Zhang  X, Brown  S, Holland  HK et al. Haploidentical  transplantation  using  
T cell replete peripheral  blood  stem cells  and myeloablative  conditioning in patients  with  high -risk hematologic 
malignancies  who  lack conventional  donors  is well tolerated  and produces  excellent  relapse- free survival:  results  of 
a prospective  phase  II trial.  Biology  of blood  and marrow  transplantation  : journal  of the American  Society  for Blood  
and Marrow  Transplantation.18(12):1859- 66.  
28. Luznik  L, O'Donnell  P, Symons  H, Chen  A, Leffell  M, Zahurak M et al. HLA-haploidentical  bone  marrow  
transplantation  for hematologic malignancies  using  nonmyeloablative  conditioning and high -dose,  
posttransplantation  cyclophosphamide.  BBMT.  2008;14(6):641- 50.  
29. Mayumi  H, Good  R. Long -lasting skin allograft  tolerance  in adult  mice  induced across  fully  allogeneic (multimajor  
H-2 plus multiminor  histocompatibility)  antigen  barriers  by a tolerance -inducing  method  using  cyclophosphamide.  J 
Exp Med.  1989;169(1):213- 38.  
30. Eto M, Mayumi  H, Tomita  Y, Yoshikai  Y, Nishimura  Y, Nomoto K. Sequential  mechanisms  of cyclophosphamide -
induced skin allograft  tolerance  including the intrathymic  clonal  deletion  followed  by [CONTACT_496248].  J Immunol.  1990;145(5):1303 -10.  
31. Luznik  L, Jalla  S, Engstrom  L, Iannone  R, Fuchs  E. Durable  engraftment  of major  histocompatibility  complex –
incompatible  cells  after  nonmyeloablative  conditioning with  fludarabine,  low-dose  total  body irradiation,  and 
posttransplantation  cyclophosphamide.  Blood.  2001;98:3456- 64.  
32. Luznik  L, O'Donnell  PV, Symons  HJ, Chen  AR, Leffell  MS, Zahurak M et al. HLA-haploidentical  bone  marrow  
transplantation  for hematologic malignancies  using  nonmyeloablative  conditioning and high -dose,  
posttransplantation  cyclophosphamide.  Biology  of blood  and marrow  transplantation  : journal  of the American  
Society  for Blood  and Marrow  Transplantation.  2008;14(6):641- 50. doi:10.1016/j.bbmt.2008.03.005.  
33. McCurdy SR, Kanakry  JA, Showel  MM,  Tsai HL, Bolanos -Meade J, Rosner  GL et al. Risk-stratified  outcomes  of 
nonmyeloablative  HLA-haploidentical  BMT  with  high -dose  posttransplantation  cyclophosphamide.  Blood.  
2015;125(19):3024 -31. doi:10.1182/blood -2015 -01-623991.  
34. Showel  MM,  Fuchs  EJ, Varadhan  R, Levis  MJ, Jones  RJ. Related  Nonmyeloablative  Haploidentical  (mini -haplo)  
Blood  or Marrow  Transplantation  (BMT) with  High -Dose  Post- Transplant  Cyclophosphmade  (PTCy)  for Acute  
Myeloid  Leukemia  (AML):  Donor  Age Impacts  Outcome Blood  (ASH  Annual  Meeting  Abstracts).  2015 126:  151(23).   
35. Kanakry  JA, Gocke  CD, Bolanos -Meade J, Gladstone  DE, Swinnen  LJ, Blackford  AL et al. Phase  II Study of 
Nonmyeloablative  Allogeneic Bone  Marrow  Transplantation  for B Cell Lymphoma  with  Post- Transplantation  
Rituximab  and Donor  Selection  Based  First  on Non -HLA Factors.  Biology  of blood  and marrow  transplantation  : 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  54 journal  of the American  Society  for Blood  and Marrow  Transplantation.  2015;21(12):2115- 22. 
doi:10.1016/j.bbmt.2015.07.012.  
36. Ciurea  S, Zhang  M, Bacigalupo  A, Bashey  A, Appelbaum  F, Aljitawi  O et al. Haploidentical  transplant  with  post -
transplant  cyclophosphamide  versus  matched  unrelated  donor  transplant  for acute  myeloid  leukemia.  Blood.  
2015;126(8):1033 -40.  
37. McCurdy S, Kanakry  J, Showel  M, Tsai H, Bolaños -Meade J, Rosner  G et al. Risk-stratified  outcomes  of 
nonmyeloablative  HLA-haploidentical  BMT  with  high -dose  posttransplantation  cyclophosphamide.  Blood.  
2015;125(19):[ADDRESS_637905] -transplantation  cyclophosphamide.  
Haematologica.  2017;102(2):391- 400.   
39. Bashey  A, Zhang  X, Sizemore C, Manion  K, Brown  S, Holland  H et al. T-Cell–Replete HLA-Haploidentical  
Hematopoietic  Transplantation  for Hematologic Malignancies  Using  Post- Transplantation  Cyclophosphamide  
Results  in Outcomes  Equivalent  to Those  of Contemporaneous  HLA-Matched  Related  and Unrelated  Donor  
Transplantation.  JCO.  2013;31(10):1310 -6.  
40. Brunstein CG, Fuchs  EJ, Carter  SL, Karanes  C, Costa  LJ, Wu J et al. Alternative  donor  transplantation  after  
reduced  intensity  conditioning:  results  of parallel  phase  [ADDRESS_637906]  blood  grafts.  Blood.118(2):282 -8.  
41. Kanate  A, Mussetti  A, Kharfan -Dabaja M, Ahn K, DiGilio  A, Beitinjaneh  A et al. Reduced- intensity  transplantation  
for lymphomas  using  haploidentical  related  donors  vs HLA-matched  unrelated  donors.  Blood.  2016;127:938- 47.  
42. Ghosh  N, Karmali  R, Rocha  V, Ahn K, DiGilio  A, Hari P et al. Reduced -Intensity  Transplantation  for Lymphomas  
Using  Haploidentical  Related  Donors  Versus  HLA-Matched  Sibling Donors:  A Center  for International  Blood  and 
Marrow  Transplant  Research  Analysis.  JCO.  2016;34(26):3141- 9.  
43. Brunstein CG, Fuchs  EJ, Carter  SL, Karanes  C, Costa  LJ, Wu J et al. Alternative  donor  transplantation  after  
reduced  intensity  conditioning:  results  of parallel  phase  [ADDRESS_637907]  blood  grafts.  Blood.  2011;118(2):282 -8. doi:10.1182/blood -[ADDRESS_637908] -
transplantation  cyclophosphamide.  Biology  of blood  and marrow  transplantation  : journal  of the American  Society  
for Blood  and Marrow  Transplantation.  2014;20(5):724- 9. doi:10.1016/j.bbmt.2014.02.001.  
45. Ciurea  SO, Zhang  MJ, Bacigalupo  AA, Bashey  A, Appelbaum  FR, Aljitawi  OS et al. Haploidentical  transplant  with  
posttransplant  cyclophosphamide  vs matched  unrelated  donor  transplant  for acute  myeloid  leukemia.  Blood.  
2015;126(8):1033 -40. doi:10.1182/blood -[ADDRESS_637909] -transplant  cyclophosphamide  for hematologic  malignanices  following a 
myeloablative  conditioning:  an update.  Bone  marrow  transplantation.  2015;[ADDRESS_637910]  2:S37- 9. 
doi:10.1038/bmt.2015.93.  
47. Cieri  N, Greco  R, Crucitti  L, Morelli  M, Giglio  F, Levati  G et al. Post- transplantation  Cyclophosphamide  and 
Sirolimus  after  Haploidentical  Hematopoietic  Stem Cell Transplantation  Using  a Treosulfan -based  Myeloablative  
Conditioning  and Peripheral  Blood  Stem Cells.  Biology  of blood  and marrow  transplantation  : journal  of the 
American  Society  for Blood  and Marrow  Transplantation.  2015;21(8):1506 -14. doi:10.1016/j.bbmt.2015.04.025.  
48. Kanate  AS, Mussetti  A, Kharfan -Dabaja MA, Ahn KW, DiGilio  A, Beitinjaneh  A et al. Reduced -intensity  
transplantation  for lymphomas  using  haploidentical  related  donors  vs HLA-matched  unrelated  donors.  Blood.  
2016;127(7):938- 47. doi:10.1182/blood -2015- 09-671834.  
49. Brammer  JE, Khouri  I, Gaballa  S, Anderlini  P, Tomuleasa  C, Ahmed  S et al. Outcomes  of Haploidentical  Stem  Cell 
Transplantation  for Lymphoma  with  Melphalan -Based  Conditioning.  Biology  of blood  and marrow  transplantation  : 
journal  of the American  Society  for Blood  and Marrow  Transplantation.  2016;22(3):493 -8. 
doi:10.1016/j.bbmt.2015.10.015.  
50. Gaballa  S, Ge I, El Fakih  RO, Brammer  JE, Wang  SA, Lee DA et al. Results  of a Two -Arm  Phase  II Clinical  Trial  Using  
Post- Transplantation  Cyclophosphamide  for Prevention  of Graft -Versus -Host  Disease  in Haploidentical  and 
Mismatched  Unrelated  Donors  Hematopoietic  Stem -Cell Transplantation.  Blood  (ASH  Annual  Meeting  Abstracts).  
2015;126:  152.   
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  55 51. Brunstein C, Fuchs  E, Carter  S, Karanes  C, Costa  L, Wu J et al. Alternative  donor  transplantation  after  reduced  
intensity  conditioning:  results  of parallel  phase  [ADDRESS_637911]  blood  grafts.  Blood.  2011;118(2):282 -8.  
52. Damlaj  M, Alkhateeb  HB, Partain  DK, Almasri  J, Hefazi  M, Hashmi  SK et al. Fludarabine  Busulfan Compared  to 
Fludarabine  Melphalan  Is Associated  with  Increased  Relapse  Risk in Reduced  Intensity  Conditioning  Transplant  
Despi[INVESTIGATOR_496223].  Blood  (ASH  Annual  Meeting  Abstracts).  2015 126:  736(23).   
53. Vokurka S, Steinerova  K, Karas  M, Koza V. Characteristics  and risk factors  of oral mucositis  after  allogeneic stem  
cell transplantation  with  FLU/MEL  conditioning regimen  in context  with  BU/CY2.  Bone  Marrow  Transplant.  
2009;44(9):601- 5. doi:10.1038/bmt.2009.66.  
54. Anasetti  C, Logan  B, Lee S, Waller  E, Weisdorf D, Wingard  J et al. Peripheral -Blood  Stem  Cells  versus  Bone  
Marrow  from Unrelated  Donors.  NEJM.  2012;367:1487- 96.  
55. Bashey  A, Zhang  M, McCurdy S, StMartin  A, Argall  T, Anasetti  C et al. Mobilized  Peripheral  Blood  Stem Cells  
Versus  Unstimulated  Bone  Marrow  As a Graft  Source  for T-Cell-Replete Haploidentical  Donor  Transplantation  Using  
Post- Transplant  Cyclophosphamide.  JCO.  2017;35(26):3002 -9.  
56. O'Donnell  P, Eapen  M, Horowitz M, Logan  B, DiGilio  A, Brunstein C et al. Comparable  outcomes  with  marrow  or 
peripheral  blood  as stem cell sources  for hematopoietic  cell transplantation  from haploidentical  donors  after  non-
ablative  conditioning:  a matched -pair analysis.  BMT.  2016;51:1599- 601.   
57. O'Donnell  P, Luznik  L, Jones  R, Vogelsang G, Leffell  M, Phelps  M et al. Nonmyeloablative  bone  marrow  
transplantation  from partially  HLA-mismatched  related  donors  using  posttransplantation  cyclophosphamide.  BBMT.  
2002;8(7):377 -86.  
58. L G, JS M, MB M, TA G, BM S, JT S et al. Pharmacodynamics  of mycophenolate  mofetil  after  nonmyeloablative  
conditioning and unrelated  donor  hematopoietic  cell transplantation.  Blood.  2005;106(13):4381- 8.  
59. P J, J R, JN B, K G, J N, D W et al. Relationship  of mycophenolic  acid exposure  to clinical  outcome  after  
hematopoietic  cell transplantation.  Clin Pharmacol  Ther.  2005;78(5):486 -500.   
60. Bejanyan  N, Rogosheske  J, Cao Q, Lazaryan  A, Holtan  S, Ustun  C et al. Weight -Based  Mycophenolate  Mofetil  
Dosing Predicts  Acute  Gvhd  and Relapse  after  Allogeneic Hematopoietic  Cell Transplantation.  BBMT.  
2018;24(3):s291.   
61. McDonald  G, Slattery  J, Bouvier  M, Ren S, Batchelder  A, Kalhorn  T et al. Cyclophosphamide  metabolism,  liver  
toxicity,  and mortality  following hematopoietic  stem cell transplantation.  Blood.  2003;101:2043 -8.  
62. Pi[INVESTIGATOR_1946]  N, Ludeman  S, Dolan  M. Pharmacogenetic  studies  related  to cyclophosphamide -based  therapy.  
Pharmacogenomics.  2009;10(12):1897.   
63. Bachanova V, Shanley R, Malik  F, Chauhan L, Lamba  V, Weisdorf D et al. Cytochrome  P450 2B6*5  Increases  
Relapse  after  Cyclophosphamide -containing Conditioning  and Autologous  Transplantation  for Lymphoma.  BBMT.  
2015;21(5):944- 8.  
64. Dandara C, Swart  M, Mpeta  B, Wonkam  A, Masimirembwa  C. Cytochrome  P450 pharmacogenetics  in African  
populations:  implications  for public  health.  Expert  Opi[INVESTIGATOR_496224]  & Toxicology.  2014;10(6):769 -85. 
doi:10.1517/17425255.2014.894020.  
65. Claudio -Campos  K, Duconge  J, Cadilla  CL, Ruaño  G. Pharmacogenetics  of drug -metabolizing enzymes  in US 
Hispanics.  Drug metabolism and personalized  therapy.  2015;30(2):87- 105.  doi:10.1515/dmdi -2014- 0023.  
66. Bejanyan  N, Pi[INVESTIGATOR_43221]  J, Wang  X, Thapa  R, Nishihori  T, Elmariah  H et al. A Phase  II Study of Sirolimus -Based  
Calcineurin  Inhibitor -Free Gvhd  Prophylaxis  after  Peripheral  Blood  Haploidentical  Transplantation  with  Post-
Transplant  Cyclophosphamide.  BBMT.  2019;12(133).   
67. Kroger  N, Iacobelli  S, Franke  G-N, Platzbecker  U, Uddin R, Hubel  K et al. Dose -Reduced Versus  Standard  
Conditioning  Followed  by [CONTACT_496249] -Cell Transplantation  for Patients  With  Myelodysplastic Syndrome:  A 
Prospective  Randomized  Phase  III Study of the EBMT  (RICMAC  Trial).  JCO.  2017;35(19):2157- 64.  
68. Scott  BL, Pasquini  MC, Logan  BR, Wu J, Devine  SM, Porter  DL et al. Myeloablative  versus  reduced -intensity  
hematopoietic  cell transplantation  for acute  myeloid  leukemia  and myelodysplastic  syndromes.  Journal  of Clinical  
Oncology.  2017;35(11):1154 -61.  
69. Eapen  M, Brazauskas  R, Hemmer  M, Perez  W, Steinert  P, Horowitz M et al. Hematopoietic  cell transplant  for 
acute  myeloid  leukemia  and myelodysplastic  syndrome:  conditioning regimen  intensity.  Blood  Advances.  
2018;2:2095- 103.   
 
 
RIC Haplo -HCT for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637912] for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637913] for Hematologic Malignancies  Version 10 
Protocol MCC # [ADDRESS_637914] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  59  
APPENDIX I I – KARNOFSKY PERFORMANCE STATUS  
Karnofsky Performance Scale  
Percent  Description  
100 Normal, no complaints, no evidence of disease.  
90 Able to carry on normal activity; minor signs or symptoms of disease.  
80 Normal activity with effort; some signs or symptoms of disease.  
[ADDRESS_637915] of his/her needs.  
[ADDRESS_637916] for Hematologic Malignancies  Version 10 
Protocol MCC # [ZIP_CODE] 22 Nov 2024 
  60 APPENDIX II I – TBI GUIDELINES  
 
All patients who have had previous radiation therapy or TBI will be seen by [CONTACT_496250] [ADDRESS_637917] feels that even a relatively small dose of total body irradiation (TBI) 
cannot safely be given.   
The dose of TBI will be 200 cGy given in a single fraction on Day - 1. 
The dose rate will be between 10- 19 cGy/minute prescribed to the midplane of the patient at the level of 
the umbilicus.  
The TBI will be delivered with right and left lateral fields with the patient semi -recumbent in a semi -fetal 
position with their arms at their sides.  
Based on measurement of transverse thickness, aluminum compensators will be used to ensure that the dose homogeneity across the fields is within 10% of the prescribed dose. Usually head/ neck, leg and lung compensators are used (although based on calculated mid- mediastinal doses, lung compensators are 
often not needed if the thickness of the arms, which partially shield the lung, are taken into the thickness consideration).  
TBI will be delivered with a linear accelerator using 6, 10, or 18 MV photons. The energy used will be 
based on the calculated dose to midline at points along the patient's torso. The lowest energy that gives 
90-100% of the prescriptions point dose will be used.  
A beam "spoiler" will be used to ensure a full skin dose.  
Half value layer lung and kidney blocks will not be utilized for patients who have not previously received 
total body irradiation.  